<SEC-DOCUMENT>0001096906-25-001281.txt : 20250812
<SEC-HEADER>0001096906-25-001281.hdr.sgml : 20250812
<ACCEPTANCE-DATETIME>20250812155142
ACCESSION NUMBER:		0001096906-25-001281
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		42
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250812
DATE AS OF CHANGE:		20250812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		251206401

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84070
		BUSINESS PHONE:		8015215301

	MAIL ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>utmd-20250630_10q.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://www.utahmed.com/20250630" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D250101_250630" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="D250101_250630" id="fact2">--12-31</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D250101_250630" id="fact3">false</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="D250101_250630" id="fact4">2025</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="D250101_250630" id="fact5">Q2</ix:nonNumeric>
</ix:hidden>
<ix:references>
	<link:schemaRef xlink:type="simple" xlink:href="utmd-20250630.xsd"/>
</ix:references>
<ix:resources>
<i:unit id="USD">
<i:measure>iso4217:USD</i:measure>
</i:unit>
<i:unit id="Shares">
<i:measure>xbrli:shares</i:measure>
</i:unit>
<i:unit id="UsdPerShare">
<i:divide>
<i:unitNumerator>
<i:measure>iso4217:USD</i:measure>
</i:unitNumerator>
<i:unitDenominator>
<i:measure>xbrli:shares</i:measure>
</i:unitDenominator>
</i:divide>
</i:unit>
<i:unit id="Pure">
<i:measure>xbrli:pure</i:measure>
</i:unit>
<i:context id="D250101_250630">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="E25Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="I250811">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2025-08-11</i:instant>
</i:period>
</i:context>
<i:context id="E24">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y25Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="E23">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y25Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E25Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E25Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E25Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E25Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E25Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-03-31</i:instant>
</i:period>
</i:context>
<i:context id="Y25Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="E25Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E24Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="D250101_250630_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-Obstetrics">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-Obstetrics_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-Obstetrics_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-Obstetrics">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-Neonatal">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-Neonatal_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-Neonatal_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-Neonatal">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q2_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-04-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-Obstetrics_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-Obstetrics_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-Neonatal_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-Neonatal_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250630_StScenario-SingleOperatingSeg">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-06-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240630_StScenario-SingleOperatingSeg">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-06-30</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">UNITED STATES</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Washington, D.C. &#160;20549</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="D250101_250630" escape="true" id="ixv-6740">10-Q</ix:nonNumeric></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="D250101_250630" format="ixt-sec:boolballotbox" id="ixv-6741">&#9746;</ix:nonNumeric> &#160;&#160; &#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D250101_250630" format="ixt:date-monthname-day-year-en" id="ixv-6742">June 30, 2025</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">OR</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="D250101_250630" format="ixt-sec:boolballotbox" id="ixv-6743">&#9744;</ix:nonNumeric> &#160;&#160; &#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Commission File No. <span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D250101_250630" escape="true" id="ixv-6744">001-12575</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D250101_250630" escape="true" id="ixv-6745">UTAH MEDICAL PRODUCTS INC</ix:nonNumeric></span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(Exact name of Registrant as specified in its charter)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D250101_250630" escape="true" id="ixv-6746">UT</ix:nonNumeric>AH</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D250101_250630" escape="true" id="ixv-6747">87-0342734</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of incorporation or organization)</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(I.R.S. Employer&#160;Identification No.)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D250101_250630" escape="true" id="ixv-6748">7043 South 300 West</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D250101_250630" escape="true" id="ixv-6749">Midvale</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D250101_250630" format="ixt-sec:stateprovnameen" id="ixv-6750">Utah</ix:nonNumeric> &#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D250101_250630" escape="true" id="ixv-6751">84047</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices) (Zip Code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="D250101_250630" escape="true" id="ixv-6752">801</ix:nonNumeric>) </span><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D250101_250630" escape="true" id="ixv-6753">566-1200</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Registrant&#8217;s telephone number, including area code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">Securities registered pursuant to Section 12(b) of the Act:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Title of each class:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Trading Symbol:</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Name of each exchange on which registered:</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="D250101_250630" escape="true" id="ixv-6754">Common stock, $0.01 par value</ix:nonNumeric></p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="D250101_250630" escape="true" id="ixv-6755">UTMD</ix:nonNumeric></p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="D250101_250630" id="ixv-6756">NASDAQ</ix:nonNumeric></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"> &#160;</kbd><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="D250101_250630" id="ixv-6757">Yes</ix:nonNumeric>&#160;<span style="font-family:Wingdings">x</span> &#160;&#160;No&#160;<span style="font-family:Wingdings">o</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"> &#160;</kbd><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="D250101_250630" id="ixv-6758">Yes</ix:nonNumeric>&#160;<span style="font-family:Wingdings">x</span> &#160;&#160;No&#160;<span style="font-family:Wingdings">o</span>&#160;</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Large accelerated filer&#160;<span style="font-family:Wingdings">o</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Accelerated filer&#160;<span style="font-family:Wingdings">o</span></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="D250101_250630" format="ixt-sec:entityfilercategoryen" id="ixv-6759">Non-accelerated filer</ix:nonNumeric> <span style="font-family:Wingdings">x</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="D250101_250630" format="ixt-sec:boolballotbox" id="ixv-6760">&#9746;</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D250101_250630" format="ixt-sec:boolballotbox" id="ixv-6761">&#9744;</ix:nonNumeric></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Wingdings">o</span> &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;Yes&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="D250101_250630" format="ixt-sec:boolballotbox" id="ixv-6762">&#9744;</ix:nonNumeric> &#160;&#160;No&#160;<span style="font-family:Wingdings">x</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock as of August 11, 2025: <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="I250811" decimals="INF" unitRef="Shares" scale="0" format="ixt:num-dot-decimal" id="ixv-6763">3,205,723</ix:nonFraction>.&#160;</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">INDEX TO FORM 10-Q</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.74%;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">PAGE</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0">PART I - FINANCIAL INFORMATION</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Item 1. Financial Statements</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Consolidated Condensed Balance Sheets as of </a><a href="#a2" style="text-decoration:none">J</a><a href="#a2" style="text-decoration:none">une 30</a><a href="#a2" style="text-decoration:none">, </a><a href="#a2" style="text-decoration:none">2025</a><a href="#a2" style="text-decoration:none"> and December 31, 2024</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">1</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a3" style="text-decoration:none">Consolidated Condensed Statements of Income for the </a><a href="#a3" style="text-decoration:none">s</a><a href="#a3" style="text-decoration:none">ix</a><a href="#a3" style="text-decoration:none"> months ended </a><a href="#a3" style="text-decoration:none">J</a><a href="#a3" style="text-decoration:none">une 30</a><a href="#a3" style="text-decoration:none">, </a><a href="#a3" style="text-decoration:none">2025</a><a href="#a3" style="text-decoration:none"> and March 31, 2024</a></span> </p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">2</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a4" style="text-decoration:none">Consolidated Condensed Statements of Cash Flows for the </a><a href="#a4" style="text-decoration:none">s</a><a href="#a4" style="text-decoration:none">ix </a><a href="#a4" style="text-decoration:none">months ended </a><a href="#a4" style="text-decoration:none">J</a><a href="#a4" style="text-decoration:none">une 30</a><a href="#a4" style="text-decoration:none">, </a><a href="#a4" style="text-decoration:none">2025</a><a href="#a4" style="text-decoration:none"> and March 31, 2024</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">3</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a5" style="text-decoration:none">Consolidated Condensed Statements of Stockholders&#8217; Equity for the </a><a href="#a5" style="text-decoration:none">s</a><a href="#a5" style="text-decoration:none">ix </a><a href="#a5" style="text-decoration:none">months ended </a><a href="#a5" style="text-decoration:none">J</a><a href="#a5" style="text-decoration:none">une 30</a><a href="#a5" style="text-decoration:none">, </a><a href="#a5" style="text-decoration:none">2025</a><a href="#a5" style="text-decoration:none"> and March 31, 2024</a></span> </p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">4</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a6" style="text-decoration:none">Notes to Consolidated Condensed Financial Statements</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">5</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a7" style="text-decoration:none">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a8" style="text-decoration:none">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">19</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a9" style="text-decoration:none">Item 4. Controls and Procedures</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">19</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">PART II &#8211;&#160;OTHER INFORMATION</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a10" style="text-decoration:none">Item 1. Legal Proceedings</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">20</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a11" style="text-decoration:none">Item 1A. Risk Factors</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">20</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a12" style="text-decoration:none">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">20</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a13" style="text-decoration:none">Item 6. Exhibits</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">21</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a14" style="text-decoration:none">SIGNATURES</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">21</p>
</td></tr>
</table>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</div>
<div style="margin-left:72pt"><a id="a1"></a><a id="a2"></a><table style="border-collapse:collapse;width:501.8pt;margin-left:5.4pt"><tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:501.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">PART I &#160;- &#160;FINANCIAL INFORMATION</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:272.9pt"><p style="font:10pt Times New Roman;margin:0"><b>Item 1. &#160;Financial Statements</b></p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:501.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:501.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED BALANCE SHEETS AS OF</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:501.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">JUNE 30, 2025 AND DECEMBER 31, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:501.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:250.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(unaudited)</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(audited)</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:272.9pt"/><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">JUNE 30, 2025</span></p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">DECEMBER 31, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:272.9pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">ASSETS</span></p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Current assets:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Cash &amp; investments</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6764">82,179</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6765">82,976</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Accounts &amp; other receivables, net</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6766">3,632</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6767">4,094</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Inventories</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6768">8,233</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6769">8,812</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Other current assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6770">331</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6771">448</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:250.7pt"><p style="font:10pt Times New Roman;margin:0">Total current assets</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6772">94,375</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6773">96,330</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Property and equipment, net</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6774">10,257</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6775">9,763</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Goodwill</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6776">14,193</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6777">13,580</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6778">56,636</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6779">53,772</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets - accumulated amortization</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6780">54,659</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6781">50,907</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets, net</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6782">1,977</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6783">2,865</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:250.7pt"><p style="font:10pt Times New Roman;margin:0">Total assets</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:Assets" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6784">120,802</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:Assets" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6785">122,538</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:250.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:272.9pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Current liabilities:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Accounts payable</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6786">737</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6787">696</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Accrued expenses</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6788">1,517</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6789">3,061</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:250.7pt"><p style="font:10pt Times New Roman;margin:0">Total current liabilities</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6790">2,254</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6791">3,757</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Deferred tax liability - Femcare IIA</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6792">389</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6793">603</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Other long term liabilities</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="E25Q2" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6794">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="E24" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6795">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Operating lease liability</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6796">256</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6797">282</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Deferred income taxes</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6798">370</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6799">469</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:250.7pt"><p style="font:10pt Times New Roman;margin:0">Total liabilities</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6800">3,269</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6801">5,111</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:250.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:272.9pt"><p style="font:10pt Times New Roman;margin:0">Stockholders' equity:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:261.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-15pt;margin-left:15pt">Common stock - $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E25Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6802"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E24" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6803">0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E25Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6804"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E24" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6805">50,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding - June 30, 2025, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E25Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6806"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E25Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6807">3,216</ix:nonFraction></ix:nonFraction> shares and December 31, 2024, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E24" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6808"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E24" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6809">3,335</ix:nonFraction></ix:nonFraction> shares</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6810">32</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6811">33</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Accumulated other comprehensive loss</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E25Q2" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6812">9,362</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E24" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6813">11,908</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Additional paid-in capital</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E25Q2" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6814">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E24" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6815">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:261.8pt"><p style="font:10pt Times New Roman;margin:0">Retained earnings</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6816">126,863</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6817">129,302</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:250.7pt"><p style="font:10pt Times New Roman;margin:0">Total stockholders' equity</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6818">117,533</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6819">117,427</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:250.7pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:93.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:111.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:250.7pt"><p style="font:10pt Times New Roman;margin:0">Total liabilities and stockholders' equity</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6820">120,802</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:93pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6821">122,538</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:272.9pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:93.1pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:111.2pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">1</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</div>
<div style="margin-left:72pt"><a id="a3"></a><table style="border-collapse:collapse;width:504pt"><tr style="height:7.2pt"><td colspan="11" valign="bottom" style="width:504pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="11" valign="bottom" style="width:504pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="11" valign="bottom" style="width:504pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND JUNE 30, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="11" valign="bottom" style="width:504pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands, except per share amounts - unaudited)</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="11" valign="bottom" style="width:504pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:151.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three Months Ended</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:151.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six Months Ended</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:151.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:151.35pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:177.75pt"/><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Sales, net</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6822">9,953</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6823">10,400</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6824">19,663</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6825">21,740</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Cost of goods sold</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6826">4,358</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6827">4,147</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6828">8,530</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6829">8,722</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0">Gross profit</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6830">5,595</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6831">6,253</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6832">11,133</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6833">13,018</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Operating expense</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:165.95pt"><p style="font:10pt Times New Roman;margin:0">Selling, general and administrative</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6834">2,264</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6835">2,560</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6836">4,495</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6837">5,176</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:165.95pt"><p style="font:10pt Times New Roman;margin:0">Research &amp; development</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:67.85pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6838">135</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6839">255</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6840">289</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6841">521</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:154.1pt"><p style="font:10pt Times New Roman;margin:0">Total operating expenses</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6842">2,399</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6843">2,815</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6844">4,784</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6845">5,697</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0">Operating income</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6846">3,196</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6847">3,438</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6848">6,349</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6849">7,321</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Other income</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:67.85pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6850">640</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6851">773</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6852">1,345</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6853">1,689</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:165.95pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-6pt;margin-left:6pt">Income before provision for income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6854">3,836</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6855">4,211</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6856">7,694</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6857">9,010</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6858">788</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6859">758</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6860">1,605</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6861">1,601</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:67.85pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6862">3,048</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6863">3,453</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6864">6,089</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6865">7,409</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (basic)</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y25Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6866">0.94</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6867">0.98</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D250101_250630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6868">1.86</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D240101_240630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6869">2.07</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (diluted)</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y25Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6870">0.94</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6871">0.98</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D250101_250630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6872">1.86</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D240101_240630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6873">2.07</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Shares outstanding - basic</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y25Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6874">3,246</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6875">3,532</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D250101_250630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6876">3,278</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D240101_240630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6877">3,579</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Shares outstanding - diluted</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y25Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6878">3,246</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6879">3,532</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D250101_250630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6880">3,278</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D240101_240630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6881">3,579</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:177.75pt"><p style="font:10pt Times New Roman;margin:0">Other comprehensive income (loss):</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:165.95pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-6pt;margin-left:6pt">Foreign currency translation net of taxes of $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y25Q2" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-6882"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y24Q2" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-6883"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="D250101_250630" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-6884"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="D240101_240630" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-6885">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in all periods</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6886">1,828</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6887">33</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6888">2,546</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6889">664</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:154.1pt"><p style="font:10pt Times New Roman;margin:0">Total comprehensive income</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:67.85pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:50pt"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6890">4,876</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:69.95pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:52pt"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6891">3,420</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:71.25pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:53pt"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6892">8,635</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:66.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:49pt"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6893">6,745</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:154.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:67.85pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="5" valign="bottom" style="width:257.4pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:69.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:71.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:66.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">2</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a4"></a><table style="border-collapse:collapse;width:100%"><tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:100%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:100%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:100%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND JUNE 30, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:100%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands - unaudited)</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:100%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.16%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:60.3%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:29.88%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six Months Ended<br/>June 30,</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"/><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM OPERATING ACTIVITIES:</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6894">6,089</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6895">7,409</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Adjustments to reconcile net income to net<br/> &#160;cash provided by operating activities</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Depreciation</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6896">405</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6897">327</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6898">1,048</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6899">1,023</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Provision for (recovery of) losses on accounts receivable</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="D250101_250630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6900">7</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6901">6</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Amortization of Right-of-Use Assets</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6902">26</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6903">26</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Deferred income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="D250101_250630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6904">360</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6905">364</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Stock-based compensation expense</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6906">168</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6907">131</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Tax benefit attributable to exercise of stock options</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="D250101_250630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6908">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6909">20</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"> Changes in operating assets and liabilities:</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:63.46%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Accounts receivable and other receivables</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" contextRef="D250101_250630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6910">409</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6911">297</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:63.46%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Inventories</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="D250101_250630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6912">908</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6913">441</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:63.46%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Prepaid expenses and other current assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D250101_250630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6914">145</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6915">45</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:63.46%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Accounts payable</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6916">37</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6917">66</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:63.46%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Accrued expenses</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="D250101_250630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6918">1,531</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6919">783</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.16%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:60.3%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Total adjustments</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6920">1,248</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6921">629</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:3.16%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.3%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Net cash provided by operating activities</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6922">7,337</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6923">8,038</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.16%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:60.3%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM INVESTING ACTIVITIES:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Capital expenditures for:</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Property and equipment</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6924">235</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6925">132</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Intangible assets</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D250101_250630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6926">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6927">5</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:66.66%"><p style="font:10pt Times New Roman;margin:0">Proceeds from sale of property and equipment</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="D250101_250630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6928">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6929">27</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.16%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.3%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Net cash used in investing activities</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D250101_250630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6930">235</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6931">110</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:3.16%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.3%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM FINANCING ACTIVITIES:</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Proceeds from issuance of common stock - options</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D250101_250630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6932">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6933">390</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6934">6,708</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6935">9,393</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Payment of dividends</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6936">2,018</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6937">2,170</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.16%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.3%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Net cash used in financing activities</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D250101_250630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6938">8,726</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6939">11,173</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:3.16%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.3%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Effect of exchange rate changes on cash</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6940">827</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6941">404</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Net increase in cash and cash equivalents</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D250101_250630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6942">797</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D240101_240630" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6943">3,649</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Cash at beginning of period</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6944">82,976</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6945">92,868</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Cash at end of period</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6946">82,179</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6947">89,219</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.2%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:3.16%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:60.3%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="5" valign="bottom" style="background-color:#D3F0FE;width:70.12%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Cash paid during the period for income taxes</p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6948">2,327</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6949">2,791</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:3.06%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:66.66%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">Cash paid during the period for interest</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:75pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="D250101_250630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6950">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:60pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="D240101_240630" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6951">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:69.72%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:0.42%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:16.34%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:0.38%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.14%;padding-top:0.75pt;padding-left:0.75pt;padding-right:0.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">3</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
</div>
<div style="margin-left:50.4pt;width:678.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"></p>
<a id="a5"></a><table style="border-collapse:collapse;width:100%"><tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">UTAH MEDICAL PRODUCTS, INC.</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Three Months and Six Months Ended June 30, 2025 and 2024</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">(In thousands - unaudited)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Accumulated</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Additional</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Other</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:19.3%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Common Stock</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Paid-in</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Comprehensive</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Retained</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Stockholders'</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"/><td valign="bottom" style="width:8.6%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Shares</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.58%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Amount</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.56%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Capital</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.52%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Income</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.56%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Earnings</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.56%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Equity</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Balance at December 31, 2024</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6952">3,335</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6953">33</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6954">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6955">11,908</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6956">129,302</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6957">117,427</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Stock option compensation expense</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6958">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6959">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6960">82</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6961">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6962">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6963">82</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6964">54</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6965">1</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6966">82</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6967">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6968">3,138</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6969">3,221</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Foreign currency translation adjustment</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6970">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6971">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6972">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6973">718</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6974">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6975">718</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Common stock dividends</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6976">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6977">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6978">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6979">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6980">1,001</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6981">1,001</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6982">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6983">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6984">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6985">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6986">3,041</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6987">3,041</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Balance at March 31, 2025</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.6%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E25Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6988">3,281</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.58%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6989">33</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6990">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.52%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6991">11,190</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6992">128,204</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6993">117,047</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Stock option compensation expense</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6994">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6995">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6996">86</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6997">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6998">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6999">86</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7000">65</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7001">1</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7002">86</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7003">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7004">3,402</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q2" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7005">3,488</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Foreign currency translation adjustment</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7006">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7007">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7008">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7009">1,828</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7010">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7011">1,828</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Common stock dividends</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7012">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7013">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7014">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7015">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7016">988</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7017">988</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7018">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7019">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7020">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7021">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7022">3,048</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7023">3,048</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Balance at June 30, 2025</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.6%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E25Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7024">3,216</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.58%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7025">32</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7026">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.52%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7027">9,362</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7028">126,862</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7029">117,533</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Balance at December 31, 2023</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7030">3,630</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7031">36</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7032">593</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7033">10,658</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7034">138,341</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7035">128,313</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7036">2</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7037">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7038">96</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7039">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7040">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7041">96</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Stock option compensation expense</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7042">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7043">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7044">79</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7045">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7046">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7047">79</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7048">43</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7049">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7050">769</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7051">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7052">2,221</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7053">2,990</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Foreign currency translation adjustment</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7054">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7055">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7056">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7057">631</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7058">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7059">631</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Common stock dividends</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7060">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7061">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7062">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7063">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7064">1,081</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7065">1,081</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7066">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7067">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7068">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7069">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7070">3,956</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7071">3,956</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Balance at March 31, 2024</p>
</td><td valign="middle" style="width:8.6%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7072">3,588</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.58%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7073">36</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7074">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:14.52%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7075">11,289</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7076">138,995</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:12.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7077">127,742</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7078">6</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7079">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7080">294</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7081">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7082">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7083">294</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Stock option compensation expense</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7084">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7085">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7086">52</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7087">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7088">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7089">52</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7090">95</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7091">1</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7092">346</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7093">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7094">6,056</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q2" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7095">6,403</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Foreign currency translation adjustment</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7096">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7097">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7098">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7099">33</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7100">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q2" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7101">33</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Common stock dividends</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7102">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7103">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7104">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7105">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7106">1,052</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7107">1,052</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.02%"><p style="font:8pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:8.6%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7108">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7109">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7110">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7111">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7112">3,453</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7113">3,453</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.02%"><p style="font:8pt Times New Roman;margin:0">Balance at June 30, 2024</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.6%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7114">3,499</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.58%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7115">35</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7116">0</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.52%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:83pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7117">11,322</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:55pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7118">135,339</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.56%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:69pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7119">124,052</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="2" valign="bottom" style="width:32.62%"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.58%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:14.52%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:10.56%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:2.12%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:12.56%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">4</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a6"></a><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(unaudited)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="D250101_250630" escape="true" id="ixv-3489"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(1)</kbd><kbd style="margin-left:19.8pt"></kbd>The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2024. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&#160;</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="D250101_250630" escape="true" id="ixv-3494"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. &#160;ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting AUS 2023-09.</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. &#160;ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting ASU 2024-03. </p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="D250101_250630" escape="true" continuedAt="c1" id="ixv-3503"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(3)</kbd><kbd style="margin-left:19.8pt"></kbd>Inventories at June 30, 2025 and December 31, 2024 consisted of the following:&#160;</p>
<ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="D250101_250630" escape="true" continuedAt="c2" id="ixv-3507"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</ix:nonNumeric></ix:nonNumeric></div>
<div style="margin-left:72pt"><ix:continuation id="c1" continuedAt="c3"><ix:continuation id="c2" continuedAt="c4"><table style="border-collapse:collapse;margin-left:9.9pt"><tr style="height:9.45pt"><td valign="top" style="width:119.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:23.35pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:88.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td valign="top" style="width:16.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:104.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31,</p>
</td></tr>
<tr style="height:9.45pt"><td valign="top" style="width:119.75pt"/><td valign="top" style="width:23.35pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:88.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="top" style="width:16.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:104.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:9.45pt"><td valign="top" style="background-color:#D3F0FE;width:119.75pt"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.35pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:88.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7120">971</ix:nonFraction></kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:16.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:104.65pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7121">1,913</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:9.45pt"><td valign="top" style="width:119.75pt"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td valign="top" style="width:23.35pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:88.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7122">1,407</ix:nonFraction></kbd>&#160;</p>
</td><td valign="top" style="width:16.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:104.65pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7123">1,414</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:9.45pt"><td valign="top" style="background-color:#D3F0FE;width:119.75pt"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.35pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:88.1pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7124">5,855</ix:nonFraction></kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:16.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:104.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7125">5,485</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:9.45pt"><td valign="top" style="width:119.75pt"><p style="font:10pt Times New Roman;margin:0">Total </p>
</td><td valign="top" style="width:23.35pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:88.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7126">8,233</ix:nonFraction></kbd>&#160;</p>
</td><td valign="top" style="width:16.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:104.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7127">8,812</ix:nonFraction></kbd>&#160;</p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c3"><ix:continuation id="c4"></ix:continuation></ix:continuation><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="D250101_250630" escape="true" id="ixv-3594"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(4)</kbd><kbd style="margin-left:18pt"></kbd>Stock-Based Compensation.  At June 30, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended June 30, 2025 and 2024, the Company recognized $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7130">86</ix:nonFraction> and $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7131">52</ix:nonFraction>, respectively, in stock-based compensation expense. &#160;In the six months ended June 30, 2025 and 2024, the Company recognized $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7132">168</ix:nonFraction> and $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7133">131</ix:nonFraction>, respectively, in stock-based compensation expense.&#160;</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:ProductWarrantyDisclosureTextBlock" contextRef="D250101_250630" escape="true" id="ixv-3600"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(5) </kbd><kbd style="margin-left:18pt"></kbd>Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024 or June 30, 2025. </p>
</ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">5</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="D250101_250630" escape="true" continuedAt="c5" id="ixv-3611"><p style="font:10pt Times New Roman;margin:0">(6) &#160;Global 2Q 2025 revenues (USD) by product category:</p>
<ix:nonNumeric name="fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock" contextRef="D250101_250630" escape="true" continuedAt="c6" id="ixv-3613"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</ix:nonNumeric></ix:nonNumeric></div>
<div style="margin-left:72pt"><ix:continuation id="c5" continuedAt="c7"><ix:continuation id="c6" continuedAt="c8"><table style="border-collapse:collapse"><tr><td valign="top" style="width:180pt"/><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:48.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-Obstetrics_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7134">818</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-Obstetrics_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7135">207</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:48.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-Obstetrics" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7136">1,025</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7137">2,421</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7138">2,386</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:48.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7139">4,807</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-Neonatal_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7140">1,737</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-Neonatal_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7141">365</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:48.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-Neonatal" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7142">2,102</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7143">889</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7144">1,130</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:48.35pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7145">2,019</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7146">5,865</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7147">4,088</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7148">9,953</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c7" continuedAt="c9"><ix:continuation id="c8" continuedAt="c10"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 1H 2025 revenues (USD) by product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt"><ix:continuation id="c9" continuedAt="c11"><ix:continuation id="c10" continuedAt="c12"><table style="border-collapse:collapse"><tr><td valign="top" style="width:180pt"/><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:48.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-Obstetrics_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7149">1,650</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-Obstetrics_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7150">400</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:48.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-Obstetrics" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7151">2,050</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7152">4,751</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7153">4,952</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:48.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7154">9,703</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-Neonatal_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7155">3,358</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-Neonatal_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7156">726</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:48.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-Neonatal" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7157">4,084</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:180pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7158">1,689</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7159">2,137</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:48.35pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7160">3,826</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7161">11,448</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7162">8,215</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7163">19,663</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c11"><ix:continuation id="c12"></ix:continuation></ix:continuation><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="D250101_250630" escape="true" continuedAt="c13" id="ixv-3887"><p style="font:10pt Times New Roman;margin:0">(7) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2025.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="D250101_250630" escape="true" continuedAt="c14" id="ixv-3891"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</ix:nonNumeric></ix:nonNumeric></div>
<div style="margin-left:72pt"><ix:continuation id="c13" continuedAt="c15"><ix:continuation id="c14" continuedAt="c16"><table style="border-collapse:collapse;margin-left:5.4pt"><tr style="height:12.5pt"><td valign="top" style="width:125.65pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><i>(in thousands)</i></p>
</td><td colspan="3" valign="top" style="width:131.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td valign="top" style="width:18pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" valign="top" style="width:153pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six months ended</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:125.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top" style="width:131.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" valign="top" style="width:153pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:125.65pt"/><td valign="middle" style="width:53.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:67.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#D3F0FE;width:125.65pt"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td valign="top" style="background-color:#D3F0FE;width:53.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:72pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:67.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td valign="top" style="width:125.65pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="middle" style="width:53.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7166">3,048</ix:nonFraction></p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7167">3,453</ix:nonFraction></p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7168">6,089</ix:nonFraction></p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:67.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240630" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7169">7,409</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#D3F0FE;width:125.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:53.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:72pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:67.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td valign="top" style="width:125.65pt"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td valign="top" style="width:53.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:72pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:67.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#D3F0FE;width:125.65pt"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:53.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y25Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7170">3,246</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7171">3,532</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D250101_250630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7172">3,278</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:67.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D240101_240630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7173">3,579</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:125.65pt"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td valign="middle" style="width:53.45pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y25Q2" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-7174">-</ix:nonFraction></p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:63pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y24Q2" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-7175">-</ix:nonFraction></p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:72pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D250101_250630" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-7176">-</ix:nonFraction></p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:67.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D240101_240630" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-7177">-</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#D3F0FE;width:125.65pt"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y25Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7178">3,246</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q2" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7179">3,532</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D250101_250630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7180">3,278</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D240101_240630" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7181">3,579</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:125.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:53.45pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:63pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:72pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:67.5pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#D3F0FE;width:125.65pt"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:53.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y25Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7182">0.94</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7183">0.98</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D250101_250630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7184">1.86</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:67.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D240101_240630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7185">2.07</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:125.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td valign="middle" style="width:53.45pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y25Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7186">0.94</ix:nonFraction></p>
</td><td valign="top" style="width:15.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:63pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q2" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7187">0.98</ix:nonFraction></p>
</td><td valign="top" style="width:18pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:72pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D250101_250630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7188">1.86</ix:nonFraction></p>
</td><td valign="top" style="width:13.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:67.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D240101_240630" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7189">2.07</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c15"><ix:continuation id="c16"></ix:continuation></ix:continuation><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">6</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="D250101_250630" escape="true" id="ixv-4115"><p style="font:10pt Times New Roman;margin:0">8) Segment Information. &#160;The Company operates as one operating segment. &#160;The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its chief executive officer, who reviews financial information presented on a consolidated basis. &#160;The CODM uses consolidated gross profit margin, operating margin, and net income to assess financial performance and allocate resources. &#160;These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table presents selected financial information with respect to the Company&#8217;s single operating segment for the quarters ended June 30, 2025 and June 30, 2024:</p>
<ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="D250101_250630" escape="true" id="ixv-4119"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<table style="border-collapse:collapse;width:288.9pt"><tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top" style="width:129.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Quarter Ended June 30,</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"/><td valign="top" style="width:60.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2025</b></p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:57.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2024</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Revenues</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7192">9,953</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7193">10,400</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Less:</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Standard cost of sales</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="fil:StandardCostOfSales" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7194">3,763</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="fil:StandardCostOfSales" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7195">3,307</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other cost of sales</p>
</td><td valign="top" style="width:60.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="fil:OtherCostOfSales" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7196">595</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="fil:OtherCostOfSales" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7197">840</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7198">5,595</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7199">6,253</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="fil:GrossProfitMargin" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-7200">56.2</ix:nonFraction>%</kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="fil:GrossProfitMargin" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-7201">60.1</ix:nonFraction>%</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Sales &amp; Marketing</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7202">525</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7203">546</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Research &amp; Development</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7204">135</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7205">254</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Litigation Fees</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="fil:LitigationExpense" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7206">284</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="fil:LitigationExpense" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7207">637</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7208">540</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7209">509</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Other General &amp; Administrative</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7210">915</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7211">869</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td valign="top" style="width:60.3pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7212">3,196</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7213">3,438</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="fil:OperatingIncomeMargin" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-7214">32.1</ix:nonFraction>%</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="fil:OperatingIncomeMargin" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-7215">33.1</ix:nonFraction>%</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other Income</p>
</td><td valign="top" style="width:60.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Interest income</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherInterestAndDividendIncome" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7216">679</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherInterestAndDividendIncome" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7217">858</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other income (expense)</p>
</td><td valign="top" style="width:60.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7218">40</ix:nonFraction>)&#160;</kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7219">85</ix:nonFraction>)&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Income before income taxes</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7220">3,835</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7221">4,211</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td valign="top" style="width:60.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7222">787</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7223">758</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Net Income</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7224">3,048</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240630_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7225">3,453</ix:nonFraction>&#160;&#160;</kbd>&#160;</p>
</td></tr>
</table>
</ix:nonNumeric></ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="D250101_250630" escape="true" id="ixv-4344"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events. &#160;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements<b>.  </b>After June 30, 2025 through August 11, 2025, the Company made additional repurchases of 10,178 shares of its stock in the open market for $567, at an average price of $55.67 per share.</p>
</ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">7</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<a id="a7"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 2.</b> &#160;<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">General</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. &#160;The Company&#8217;s Form 10-K Annual Report for the year ended December 31, 2024 provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. &#160;Because of the relatively short span of time, results for any given three- or six-month period in comparison with a previous three- or six-month period may not be indicative of comparative results for the year as a whole. Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. &#160;Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&#160;or GBP = UK Pound Sterling; CAD = Canadian Dollars; and &#8364;&#160;or EUR = Euros. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Analysis of Results of Operations</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:10.8pt">a)</kbd><kbd style="margin-left:24.3pt"></kbd>Overview&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Income statement results in second calendar quarter (2Q) and first half (1H) 2025 compared to the same periods of 2024 were as follows:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;width:474.55pt;margin-left:4.25pt"><tr><td valign="top" style="width:122.15pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="2" valign="top" style="width:45.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:53.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2025</span></p>
</td><td colspan="2" valign="top" style="width:51.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:46.35pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">change</span></p>
</td><td valign="top" style="width:60.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2025</span></p>
</td><td valign="top" style="width:49.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="top" style="width:46pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">change</span></p>
</td></tr>
<tr><td colspan="2" valign="top" style="background-color:#D3F0FE;width:122.55pt"><p style="font:10pt Times New Roman;margin:0">Net Sales</p>
</td><td valign="top" style="background-color:#D3F0FE;width:45.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="top" style="background-color:#D3F0FE;width:53.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$9,953</p>
</td><td valign="top" style="background-color:#D3F0FE;width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$10,400</p>
</td><td valign="top" style="background-color:#D3F0FE;width:46.35pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> ( &#160;4.3%)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$19,663</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$21,740</p>
</td><td valign="top" style="background-color:#D3F0FE;width:46pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">( 9.6%)</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:122.55pt"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td valign="top" style="width:45.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="top" style="width:53.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,595</p>
</td><td valign="top" style="width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,253</p>
</td><td valign="top" style="width:46.35pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (10.5%)</p>
</td><td valign="top" style="width:60.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,133</p>
</td><td valign="top" style="width:49.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">13,018</p>
</td><td valign="top" style="width:46pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (14.5%)</p>
</td></tr>
<tr><td colspan="2" valign="top" style="background-color:#D3F0FE;width:122.55pt"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td valign="top" style="background-color:#D3F0FE;width:45.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="top" style="background-color:#D3F0FE;width:53.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,196</p>
</td><td valign="top" style="background-color:#D3F0FE;width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,438</p>
</td><td valign="top" style="background-color:#D3F0FE;width:46.35pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> ( &#160;7.1%)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,349</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,321</p>
</td><td valign="top" style="background-color:#D3F0FE;width:46pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (13.3%)</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:122.55pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Income Before Tax</p>
</td><td valign="top" style="width:45.1pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="top" style="width:53.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,835</p>
</td><td valign="top" style="width:50.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,211</p>
</td><td valign="top" style="width:46.35pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> ( &#160;8.9%)</p>
</td><td valign="top" style="width:60.7pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,694</p>
</td><td valign="top" style="width:49.45pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,010</p>
</td><td valign="top" style="width:46pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (14.6%)</p>
</td></tr>
<tr><td colspan="2" valign="top" style="background-color:#D3F0FE;width:122.55pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Net Income (US GAAP)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:45.1pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="top" style="background-color:#D3F0FE;width:53.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,048</p>
</td><td valign="top" style="background-color:#D3F0FE;width:50.65pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,453</p>
</td><td valign="top" style="background-color:#D3F0FE;width:46.35pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (11.7%)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.7pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,089</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.45pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,409</p>
</td><td valign="top" style="background-color:#D3F0FE;width:46pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (17.8%)</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:122.55pt"><p style="font:10pt Times New Roman;margin:0">Earnings per Diluted Share</p>
</td><td valign="top" style="width:45.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="top" style="width:53.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$0.939</p>
</td><td valign="top" style="width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$0.978</p>
</td><td valign="top" style="width:46.35pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> ( &#160;4.0%)</p>
</td><td valign="top" style="width:60.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$1.858</p>
</td><td valign="top" style="width:49.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$2.070</p>
</td><td valign="top" style="width:46pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (10.3%)</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consolidated total 2Q 2025 revenues were $447 (4.3%) lower than in 2Q 2024, with 1H 2025 revenues $2,077 (9.6%) lower than in 1H 2024. &#160;The lower sales in comparison with the prior year&#8217;s periods were dominated by a continued decline in sales to PendoTECH, representing 71% of the 2Q decline and 86% of the 1H decline. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s profit margins compared to those of the prior year&#8217;s same periods follow:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;width:484.1pt;margin-left:5.4pt"><tr><td valign="top" style="width:232.1pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt">&#160;</p>
</td><td valign="top" style="width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">2Q 2025 </p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center"><span style="border-bottom:1px solid #000000">(Apr &#8211;&#160;Jun)</span></p>
</td><td valign="top" style="width:63.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">2Q 2024</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center"><span style="border-bottom:1px solid #000000">(Apr &#8211;&#160;Jun)</span></p>
</td><td valign="top" style="width:63.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">1H 2025</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center"><span style="border-bottom:1px solid #000000">(Jan &#8211;&#160;Jun)</span></p>
</td><td valign="top" style="width:60.65pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">1H 2024</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center"><span style="border-bottom:1px solid #000000">(Jan &#8211;&#160;Jun)</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:232.1pt"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin (Gross Profit/ sales):</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">56.2%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">60.1% </p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">56.6%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.65pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">59.9%</p>
</td></tr>
<tr><td valign="top" style="width:232.1pt"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin (Operating Income/ sales):</p>
</td><td valign="top" style="width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">32.1%</p>
</td><td valign="top" style="width:63.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">33.1%</p>
</td><td valign="top" style="width:63.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">32.3%</p>
</td><td valign="top" style="width:60.65pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">33.7%</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:232.1pt"><p style="font:10pt Times New Roman;margin:0">Income B4 Tax Margin (Income Before Tax/ sales):</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">38.5%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">40.5%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">39.1%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.65pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">41.4%</p>
</td></tr>
<tr><td valign="top" style="width:232.1pt"><p style="font:10pt Times New Roman;margin:0">Net Income Margin (Net Income/ sales)<i>:</i></p>
</td><td valign="top" style="width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">30.6%</p>
</td><td valign="top" style="width:63.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">33.2%</p>
</td><td valign="top" style="width:63.75pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">31.0%</p>
</td><td valign="top" style="width:60.65pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;text-align:center">34.1%</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The 2Q percentage decline in consolidated revenues was less than for 1H primarily because the period-to-period decline in UTMD sales to its previously major biopharmaceutical OEM customer, PendoTECH, decreased from $511 in 2Q 2024 to $196 in 2Q 2025, and from $2,056 in 1H 2024 to $264 in 1H 2025. &#160;Although the negative PendoTECH sales comparisons are bottoming out, looking forward to the rest of the year, UTMD expects 2H of 2025 PendoTECH sales will be about $200 lower than in 2H 2024. &#160;This would result in sales to this OEM customer for the 2025 year as a whole to be about $2 million lower compared to year 2024, which is consistent with management&#8217;s projection provided at the beginning of 2025. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s Gross Profit margin contracted more than expected in 2Q 2025 primarily as a result of lower sales than expected and an unfavorable product mix for UTMD&#8217;s Ireland operations. Sales of devices from Utah operations maintained Gross Profit margins consistent with the prior 1Q 2025, as well as for year 2024. Operating Income declined less than the Gross Profit decline due to $355 lower 2Q 2025 U.S. litigation costs compared to 2Q 2024, and $791 lower litigation costs than in 1H 2024, which costs are included in Operating Expenses per US GAAP, despite the negative impact of a weaker USD on Operating Expenses in Ireland and the UK. &#160;Non-operating Income resulting from 2025 interest rates lower than in 2024 caused the period-to-period Income Before Tax (EBT) decline to be more than the Operating Income decline. Although a higher estimated average income tax provision rate </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">8</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">helped to increase the percentage period-to-period declines in Net Income, share repurchases during 2Q 2025 and 1H 2025 helped to significantly mitigate the decline in Earnings Per Share (EPS) relative to Net Income. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s June 30, 2025 Balance Sheet continued strong, with no debt. Ending Cash and Investments were $82.2 million compared to $83.0 million on December 31, 2024, after paying $2.0 million in cash dividends to stockholders, repurchasing $6.7 million of UTMD common stock, increasing non-cash working capital by $0.3 million (including reducing current liabilities by $1.5 million) and investing $0.2 million in capital expenditures during 1H 2025. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 2Q 2025 compared to the end of calendar year 2024 and the end of 2Q 2024 were</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;margin-left:5.4pt"><tr><td valign="top" style="width:78.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">6-30-25</span></p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">12-31-24</span></p>
</td><td valign="top" style="width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td><td valign="top" style="width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">6-30-24</span></p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:78.6pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.37213</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.25209</p>
</td><td valign="top" style="background-color:#D3F0FE;width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;&#160;9.6%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.26371</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;8.6%</p>
</td></tr>
<tr><td valign="top" style="width:78.6pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.17706</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.03505</p>
</td><td valign="top" style="width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> 13.7%</p>
</td><td valign="top" style="width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.07109</p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;9.9%</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:78.6pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.65722</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.61834</p>
</td><td valign="top" style="background-color:#D3F0FE;width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;&#160;6.3%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.66742</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;(1.5%)</p>
</td></tr>
<tr><td valign="top" style="width:78.6pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.73422</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.69428</p>
</td><td valign="top" style="width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;&#160;5.8%</p>
</td><td valign="top" style="width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.73068</p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;&#160;0.5%</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">b)</kbd><kbd style="margin-left:22.5pt"></kbd>Revenues &#160;</p>
<p style="font:10pt Times New Roman;margin:0">Terms of sale are established in advance of UTMD&#8217;s acceptance of customer orders. In the U.S., Ireland, UK, France, Canada, Australia and New Zealand, UTMD accepts orders directly from and ships directly to end user medical facilities, as well as third party medical/surgical distributors, under UTMD&#8217;s Standard Terms and Conditions (T&amp;C) of Sale. UTMD&#8217;s T&amp;C of Sale to end user facilities are substantially the same in the U.S. and OUS. UTMD also has standard T&amp;C of Sale for OEM customers, other medical device and non-medical device customers for components manufactured by UTMD, which are substantially the same, except that prices are generally quoted prior to acceptance of each order. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD may have separate discounted pricing agreements with a specific clinical facility, or group of affiliated facilities or large OEM customers based on volume of purchases. &#160;Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities or OEM customers, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year. For new customers, the customer&#8217;s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements based on volume of purchases disclosure is not inconsistent with UTMD&#8217;s disclosure that the selling price is fixed prior to the acceptance of a specific customer order. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">2Q 2025 Sales</span></p>
<p style="font:10pt Times New Roman;margin:0">Total consolidated 2Q 2025 UTMD worldwide (WW) sales in USD terms were $9,953 compared to $10,400 in 2Q 2024. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consistent with the projection in UTMD&#8217;s SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD&#8217;s previously largest OEM customer, PendoTECH, were $315 (61.7%) lower in 2Q 2025 compared to 2Q 2024. &#160;Sales to PendoTECH were $196 in 2Q 2025 compared to $511 in 2Q 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Despite the lower 2Q 2025 sales to PendoTECH, which were all domestic, aggregated 2Q 2025 domestic sales were $5,865 compared to $5,831 in 2Q 2024. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic sales are invoiced in USD and obviously not subject to foreign currency conversion (FX) rate fluctuations. The components of domestic sales include 1) &#8220;direct non-Filshie device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;domestic Filshie device sales&#8221;. UTMD separates domestic Filshie device sales from other medical device sales direct to medical facilities because UTMD is simply a distributor for Femcare in the U.S. &#160;The domestic sales increase was because 2Q 2025 sales of the Filshie Clip System in the U.S. were $1,107 compared to $1,021, 8% higher than in 2Q 2024, and 2Q 2025 direct domestic sales of other devices were $4,047 compared to $3,670, 10% higher than in 2Q 2024. U.S. Filshie direct sales were 19% of total domestic sales compared to 18% in 2Q 2024. Direct non-Filshie device </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">9</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">sales represented 69% of total domestic sales compared to 63% in 2Q 2024. &#160;In the remaining OEM domestic sales category, which includes PendoTECH, 2Q 2025 sales were $712 compared to $1,140 in 2Q 2024, 38% lower. Domestic OEM sales in 2Q 2025 were 12% of total domestic sales compared to 20% in 2Q 2024. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">On the other hand, 2Q 2025 international sales to customers outside the U.S. (OUS), were lower than expected. Total OUS sales in 2Q 2025 were $4,088 compared to $4,569 in 2Q 2024. In 2Q 2025, 37% of OUS sales were direct to medical facilities located in Ireland, the UK, France, Canada, Australia and New Zealand, compared to 39% in 2Q 2024. OUS direct to end-user sales are invoiced in foreign currencies. Despite the help from a weaker USD compared to the EUR and GBP in translating shipments invoiced in foreign currencies, 2Q 2025 OUS direct sales by UTMD&#8217;s Ireland, UK, Australia and Canada subsidiaries were just $1,503 compared to $1,785 in 2Q 2024. Canadian medical facilities openly put pressure on Canada distributors to not purchase medical devices from the U.S. In USD terms, including the impact of FX rate differences, total direct to end-user sales were $282 (15.8%) lower overall, including 21.5% lower in Ireland, 22.5% lower in Canada, 5.4% lower in the UK, 39.8% lower in Australia/New Zealand and 17.2% lower in France.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The remaining $2,585 in OUS sales in 2Q 2025, which were $200 lower than in 2Q 2024, were to distributors in other countries. These sales included export sales from the U.S. to OUS distributors invoiced in USD, and shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK invoiced in EUR and </p>
<p style="font:10pt Times New Roman;margin:0">GBP. The timing of shipments to OUS distributors can cause significant fluctuations in quarterly comparisons since distributors tend to order larger quantities each time, in order to minimize transit and other logistical costs. The threat of reciprocal tariffs which have to be paid by distributors to their respective governments may have caused a pause for some. Although exports from Utah to OUS distributors invoiced in USD were $147 (+17.2%) higher, shipments from UTMD&#8217;s Ireland and the UK subsidiaries to OUS distributors were $347 (18%) lower. Shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD&#8217;s largest BPM medical device distributor located in China were $93 higher, but Ireland shipments to OUS distributors of other devices were $441 lower. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The portion of OUS sales invoiced in foreign currencies in USD terms were 31% of total WW consolidated 2Q 2025 sales compared to 35% in 2Q 2024. The average USD FX rates increased 2Q 2025 total consolidated sales $173 for sales invoiced in foreign currencies. Actually, a stronger GBP and EUR together added $180. The CAD and AUD were weaker. &#160;FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 2Q 2025 and 2Q 2024 for revenue purposes follow:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="margin:0 auto;border-collapse:collapse"><tr style="height:4.85pt"><td valign="top" style="width:75.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:14.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2025</span></p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr style="height:10.1pt"><td valign="top" style="background-color:#D3F0FE;width:75.4pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#D3F0FE;width:14.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 1.3368</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 1.2615</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;+6.0%</p>
</td></tr>
<tr style="height:10.1pt"><td valign="top" style="width:75.4pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:14.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 1.1569</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 1.0752</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;+7.6%</p>
</td></tr>
<tr style="height:9.75pt"><td valign="top" style="background-color:#D3F0FE;width:75.4pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#D3F0FE;width:14.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:57.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 0.6394</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 0.6594</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;( 3.0%)</p>
</td></tr>
<tr style="height:10.1pt"><td valign="top" style="width:75.4pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:14.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:57.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 0.7227</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 0.7308</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;( 1.1%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The $173 weighted average favorable impact on 2Q 2025 foreign currency OUS sales was 6.0%. &#160;In constant currency terms, foreign currency sales in 2Q 2025 were 21.4% lower than in 2Q 2024. &#8220;Constant currency&#8221; sales means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared.  &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">1H 2025 Sales</span></p>
<p style="font:10pt Times New Roman;margin:0">Total consolidated 1H 2025 UTMD worldwide (WW) sales in USD terms were $19,663 compared to $21,740 in 1H 2024. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consistent with the projection in UTMD&#8217;s SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD&#8217;s previously largest OEM customer, PendoTECH, were $1,791 (87.1%) lower in 1H 2025 compared to 1H 2024. &#160;WW sales to PendoTECH were $265 in 1H 2025 (all in the U.S.) compared to $2,056 in 1H 2024 ($1,627 in the U.S. and $429 in Ireland). &#160;Aggregated 1H 2025 domestic sales at $11,448 compared to $12,022 in 1H 2024 were $574 lower, despite the 1H $1,362 lower 2025 domestic sales to PendoTECH. &#160;In other words, 1H 2025 domestic sales excluding PendoTECH were $11,184 compared to $10,396 in 1H 2024, 7.6% higher.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic sales are invoiced in USD and obviously not subject to foreign currency conversion (FX) rate fluctuations. The components of domestic sales include 1) &#8220;direct non-Filshie device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;domestic Filshie </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">10</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">device sales&#8221;. UTMD separates domestic Filshie device sales from other medical device sales direct to medical facilities because UTMD is simply a distributor for Femcare in the U.S. &#160;The non-PendoTECH domestic sales increase was because 1H 2025 sales of the Filshie Clip System in the U.S. were $2,146 compared to $2,082, 3% higher than in 1H 2024, and 1H 2025 direct domestic sales of other devices were $7,962 compared to $7,180, 11% higher than in 1H 2024. &#160;U.S. Filshie direct sales were 19% of total 1H 2025 domestic sales compared to 17% in 1H 2024. Direct non-Filshie device sales represented 70% of total domestic sales compared to 60% in 1H 2024. &#160;In the remaining OEM domestic sales category, which includes PendoTECH, 1H 2025 sales were $1,340 compared to $2,760 in 1H 2024, 51% lower. &#160;Domestic OEM sales in 1H 2025 were 12% of total domestic sales compared to 23% in 1H 2024. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">On the other hand, 1H 2025 international sales to customers outside the U.S. (OUS), were lower than expected. Total OUS sales in 1H 2025 were 15.5% lower at $8,215 compared to $9,718 in 1H 2024. Excluding PendoTECH OUS sales which were in 1Q, 1H 2024 sales were $9,289. &#160;So, OUS sales excluding PendoTECH in 1H 2025 were 11.6% lower than in 1H 2024. &#160;In both 1H 2025 and 1H 2024, 37% of OUS sales were direct to medical facilities located in Ireland, the UK, France, Canada, Australia and New Zealand. OUS direct to end-user sales are invoiced in foreign currencies. Despite the help from a weaker USD compared to the EUR and GBP in translating shipments invoiced in foreign currencies, 1H 2025 OUS direct sales by UTMD&#8217;s Ireland, UK, Australia and Canada subsidiaries were $3,079 compared to $3,609 in 1H 2024. In USD terms, including the impact of FX rate differences, total direct to end-user sales were $530 (14.7%) lower overall, including 27.4% lower in Ireland, 22.1% lower in Canada, 6.6% lower in the UK, 20.6% lower in Australia/New Zealand and 21.4% lower in France.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The remaining $5,136 in OUS sales in 1H 2025, which were $973 lower than in 1H 2024, were to distributors in other countries. These sales included export sales from the U.S. to OUS distributors invoiced in USD, and shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK invoiced in EUR and GBP. The timing of shipments to OUS distributors can cause significant fluctuations in quarterly comparisons since distributors tend to order larger quantities each time, in order to minimize transit and other logistical costs. Exports from Utah to OUS distributors invoiced in USD were $69 (3.3%) lower. &#160;Shipments from UTMD&#8217;s Ireland and the UK subsidiaries to OUS distributors were $904 (22.4%) lower. Shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD&#8217;s largest BPM medical device distributor located in China were $71 higher, but Ireland shipments to OUS distributors of other devices were $964 lower. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The portion of OUS sales invoiced in foreign currencies in USD terms were 31% of total WW consolidated 1H 2025 sales compared to 33% in 1H 2024. The average USD FX rates increased 1H 2025 total consolidated sales $130 for sales invoiced in foreign currencies. Actually, a stronger GBP and EUR together added $160. The CAD and AUD were weaker. &#160;FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1H 2025 and 1H 2024 for revenue purposes follow:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="margin:0 auto;border-collapse:collapse"><tr style="height:7.2pt"><td valign="bottom" style="width:55.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1H<br/><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="bottom" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1H<br/><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td valign="bottom" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE;width:55.95pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#D3F0FE;width:12.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">1.2977</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">1.2646</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;+2.6%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="width:55.95pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:12.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">1.1155</kbd>&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">1.0787</kbd>&#160;</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;+3.4%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE;width:55.95pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#D3F0FE;width:12.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">0.6329</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">0.6586</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;( 3.9%)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="width:55.95pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:12.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">0.7094</kbd>&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">0.7362</kbd>&#160;</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;( 3.6%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The $130 weighted average favorable impact on 1H 2025 foreign currency OUS sales was 2.2%. &#160;In constant currency terms, foreign currency sales in 1H 2025 were 18.0% lower than in 1H 2024. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">11</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table provides USD-denominated sales amounts divided into general product categories for total revenues and the subset of OUS revenues: </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:432pt;margin-left:0.9pt"><tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Global revenues by product category</span>:</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2025</span></p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2025</span></p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1,025</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> $ 1,019</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 2,050</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 2,044</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,807</p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,452</p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,703</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,912</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,102</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,546</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,084</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,188</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:58.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,019</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,383</p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,826</p>
</td><td valign="top" style="width:49.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,596</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Total:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 9,953</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$10,400</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$19,663</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$21,740</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">OUS revenues by product category</span>:</p>
<table style="border-collapse:collapse;width:432.2pt;margin-left:0.9pt"><tr><td valign="top" style="width:207.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2025</span></p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1H 2025</span></p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207.2pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;207</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;167</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;400</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;388</p>
</td></tr>
<tr><td valign="top" style="width:207.2pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,385</p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,042</p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,952</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,150</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207.2pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">365</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">315</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">726</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">711</p>
</td></tr>
<tr><td valign="top" style="width:207.2pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:58.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;1,131</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;1,045</p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;2,137</p>
</td><td valign="top" style="width:49.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;2,469</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207.2pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Total:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 4,088</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 4,569</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 8,215</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 9,718</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:24.3pt"></kbd>*includes assemblies and molded components sold to OEM customers.&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Comments on tariffs</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Tariffs on materials received from OUS suppliers are included in manufacturing costs, i.e. reducing Gross Profit. &#160;Although U.S. tariffs paid by UTMD on certain goods purchased from OUS suppliers have been minimal to date, i.e. $16 in 1H 2025 compared to $15 in 1H 2024, UTMD&#8217;s raw material suppliers in the U.S. continue to increase prices, in some cases citing &#8220;tariffs&#8221; that they paid on raw materials as justification. Although UTMD challenges this input, the second-level tariff cost impact hasn&#8217;t been quantifiable. Due to regulatory standards, UTMD can&#8217;t easily change suppliers as materials typically need to meet substantial validation for use in its medical devices.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">However, the more significant potential negative impact on UTMD is &#8220;reciprocal tariffs&#8221; charged by other countries&#8217; governments on goods sold by UTMD OUS. &#160;These tariffs are paid by UTMD&#8217;s OUS distributors or direct customers, effectively potentially substantially increasing the prices that OUS distributors and customers have to pay for UTMD devices; therefore decreasing sales. Despite the fact that products may be manufactured in Ireland or the UK and not sold by UTMD in the U.S., recent experience is that foreign governments nevertheless consider the sales as from the U.S. subject to tariffs since the manufacturers, although OUS, are subsidiaries of a U.S. corporate entity. There have been some requested delays in shipments by OUS distributors in 2025 as a result of uncertainty about the timing of possible tariffs that they might have to pay, and don&#8217;t feel that they can afford it.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">As stockholders know, as an example, UTMD&#8217;s largest distributor of BPM devices manufactured and sold by UTMD Ltd in Ireland is located in China. For the last 15 years, this distributor annually placed an order for the following year which was by agreement non-changeable and non-cancellable. Shipments to-date in 2025 from UTMD Ireland to China have been on plan, as ordered in late 2024, and $71 higher than in 1H 2024. &#160;However, the distributor has recently requested possibly delaying the final $800 (at FX 1.12 USD/EUR) shipment in 2025 to 2026 due to &#8220;possible tariffs&#8221;. &#160;If this should occur, UTMD&#8217;s projected year-end 2025 revenues of 5% less than in 2024 sales due to lower PendoTECH OEM demand, would be approximately 7% lower than in 2024 assuming that all else remains on plan. &#160;In addition, UTMD&#8217;s Ireland Gross Profit margin would suffer as the resulting substantially lower 2H 2025 shipments would not allow the expected absorption of fixed manufacturing overhead costs. &#160;Of course, this remains a highly uncertain event as a result of fluctuations in the tariff threat.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:10.8pt">c)</kbd><kbd style="margin-left:24.3pt"></kbd>Gross Profit&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Gross Profit results from subtracting the cost of goods sold, comprised of costs of production, manufacturing engineering, depreciation of equipment, maintenance and repairs, quality assurance including regulatory compliance, and purchasing including freight for receiving materials from suppliers, from revenues. The cost of goods sold is divided into three categories: direct labor, raw materials and manufacturing overhead (MOH). &#160;Direct labor and raw materials are predominantly variable costs, i.e. vary directly with revenues. &#160;MOH contains many fixed costs consistent with the Company&#8217;s infrastructure, for example, supervision and engineering personnel.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">12</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s 2Q 2025 Gross Profit was $658 (10.5%) lower than in 2Q 2024. Gross Profit in 1H 2025 was $1,885 (14.5%) lower than in 1H 2024. The consolidated 2Q 2025 Gross Profit margin was 56.2% compared to 60.1% in 2Q 2024. &#160;The 1H 2025 Gross Profit margin was 56.6% compared to 59.9% in 1H 2024. &#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The lower Gross Profit margins were primarily due to Ireland operations, as a result of an unfavorable product mix, lower sales which absorbed less fixed MOH costs, higher raw material costs and an increase in intercompany finished goods inventory manufactured in Ireland which required reserved gross profit. With absorption of MOH helped by higher direct sales, the average Gross Profit margin in the U.S. was consistent with past periods in 2024, and in the preceding 1Q 2025. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:10.8pt">d)</kbd><kbd style="margin-left:22.5pt"></kbd> Operating Income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Operating Income results from subtracting Operating Expenses from Gross Profit. &#160;Operating Expenses are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Operating Income in 2Q 2025 of $3,196 was $242 (7.1%) lower compared to 2Q 2024 Operating Income of $3,438. The lower Operating Income was the result of $658 lower Gross Profit offset by $416 lower Operating Expense, as explained below. UTMD&#8217;s 2Q 2025 Operating Income margin (Operating Income as a percentage of sales) remained a healthy 32.1%. &#160;Operating Income in 1H 2025 was $6,349 compared to $7,321 in 1H 2024, a decrease of $972 (13.3%), with a continuing healthy 1H 2025 Operating Income margin of 32.3%. &#160;The lower Operating Income was the result of $1,885 lower Gross Profit offset by $913 lower Operating Expense, as described below.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table summarizes Operating Expenses in 2Q and 1H 2025 compared to the same periods in 2024 by Operating Expense (OE) category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="bottom" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0">OE<br/><span style="border-bottom:1px solid #000000">Category</span></p>
</td><td valign="bottom" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2Q 2025</span></p>
</td><td valign="bottom" style="width:43.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="bottom" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="bottom" style="width:52.4pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="bottom" style="width:52.4pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1H 2025</span></p>
</td><td valign="bottom" style="width:52.4pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="bottom" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="bottom" style="width:52.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:59.4pt"><p style="font:10pt Times New Roman;margin:0">S&amp;M:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">524</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:27pt">5.3</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">546</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">5.3</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">1,024</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">5.2</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">958</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">4.4</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0">G&amp;A:</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">1,740</kbd>&#160;</p>
</td><td valign="top" style="width:43.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:27pt">17.5</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">2,014</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">19.4</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">3,470</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">17.6</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">4,219</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">19.4</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:59.4pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">R&amp;D:</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">135</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.8pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:27pt">1.3</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">255</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-bottom:0.5pt solid #000000;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">2.4</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">290</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">1.5</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">520</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">2.4</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0">Total OE:</p>
</td><td valign="top" style="width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">2,399</kbd>&#160;</p>
</td><td valign="top" style="width:43.8pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:27pt">24.1</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">2,815</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-top:0.5pt solid #000000;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">27.1</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">4,784</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">24.3</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">5,697</kbd>&#160;</p>
</td><td valign="top" style="width:52.4pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:34pt">26.2</kbd>&#160;</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Because of lower S&amp;M expenses in 2Q 2025 along with lower sales, S&amp;M expenses as a percentage of sales remained the same. &#160;In 1H 2025, higher expenses with lower sales increased S&amp;M expenses as a percentage of sales to 5.2% from 4.4% in 1H 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">S&amp;M Operating Expenses were $22 lower in 2Q 2025 and $66 higher in 1H 2025 compared to the same periods in 2024 respectively. UTMD in the U.S. is self-insured for its employee health plan. The lower S&amp;M expenses in 2Q 2025 compared to 2Q 2024 can be explained primarily by a lower medical expense accrual. About two-thirds of the higher 1H S&amp;M expenses were in the U.S., with increases spread about evenly among several categories: salaries and consulting fees, trade show expenses, fees paid to national distributors and lower recovered freight costs reimbursed by customers. The remaining third of the higher 1H 2025 S&amp;M expenses was about evenly split between Ireland and Australia: salaries in Australia and recovered freight costs in Ireland. The impact of differences in FX rates on foreign subsidiary S&amp;M expenses added $4 in 2Q 2025 and $2 in 1H 2025 (see below). &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">G&amp;A expenses dominate UTMD&#8217;s total Operating Expense, largely because of non-cash expenses from the amortization of Identifiable Intangible Assets (IIA) associated with the Filshie Clip System and the expenses of current litigation in the U.S. &#160;A segmentation of USD-denominated G&amp;A expenses follows: &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:458pt;margin-left:5.4pt"><tr style="height:7.2pt"><td valign="bottom" style="width:85.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000">G&amp;A Exp<br/><span style="border-bottom:1px solid #000000">Category</span></p>
</td><td valign="bottom" style="width:54pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center"><span style="border-bottom:1px solid #000000">2Q 2025</span></p>
</td><td valign="bottom" style="width:40.5pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="bottom" style="width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="bottom" style="width:40.5pt;border-right:1.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="bottom" style="width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center"><span style="border-bottom:1px solid #000000">1H 2025</span></p>
</td><td valign="bottom" style="width:36pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="bottom" style="width:55.8pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="bottom" style="width:46.7pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:85.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000">IIA Amort- UK:</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:54pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;font:9.5pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:37pt">531</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">5.3</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;font:9.5pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">501</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">4.8</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;font:9.5pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">1,032</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:36pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">5.2</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:55.8pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;font:9.5pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:38pt">1,005</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:46.7pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">4.6</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:85.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000">Other &#8211; UK:</p>
</td><td valign="middle" style="width:54pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:37pt">189</kbd>&#160;</p>
</td><td valign="middle" style="width:40.5pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td><td valign="middle" style="width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">173</kbd>&#160;</p>
</td><td valign="middle" style="width:40.5pt;border-right:1.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td><td valign="middle" style="width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">379</kbd>&#160;</p>
</td><td valign="middle" style="width:36pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000">&#160;</p>
</td><td valign="middle" style="width:55.8pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:38pt">360</kbd>&#160;</p>
</td><td valign="middle" style="width:46.7pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:85.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000">U.S. Litigation</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:54pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:37pt">280</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">2.8</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">635</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">6.1</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">587</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:36pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">3.0</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:55.8pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:38pt">1,378</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:46.7pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">6.3</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:85.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000">Other &#8211; US:</p>
</td><td valign="middle" style="width:54pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:37pt">603</kbd>&#160;</p>
</td><td valign="middle" style="width:40.5pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">6.1</p>
</td><td valign="middle" style="width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">557</kbd>&#160;</p>
</td><td valign="middle" style="width:40.5pt;border-right:1.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">5.4</p>
</td><td valign="middle" style="width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">1,197</kbd>&#160;</p>
</td><td valign="middle" style="width:36pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">6.1</p>
</td><td valign="middle" style="width:55.8pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:38pt">1,158</kbd>&#160;</p>
</td><td valign="middle" style="width:46.7pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">5.3</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:85.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000">IRE:</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:54pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:37pt">88</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">92</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">172</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:36pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center"> &#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:55.8pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:38pt">186</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:46.7pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:85.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000">AUS:</p>
</td><td valign="middle" style="width:54pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:37pt">16</kbd>&#160;</p>
</td><td valign="middle" style="width:40.5pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center"><span style="border-bottom:1px solid #000000"> &#160;&#160;</span></p>
</td><td valign="middle" style="width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">24</kbd>&#160;</p>
</td><td valign="middle" style="width:40.5pt;border-right:1.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td><td valign="middle" style="width:49.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">34</kbd>&#160;</p>
</td><td valign="middle" style="width:36pt;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td><td valign="middle" style="width:55.8pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:38pt">66</kbd>&#160;</p>
</td><td valign="middle" style="width:46.7pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:85.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><span style="border-bottom:1px solid #000000">CAN:</span></p>
</td><td valign="middle" style="background-color:#D3F0FE;width:54pt;border-bottom:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:37pt">33</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-bottom:0.5pt solid #000000;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt;border-bottom:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">32</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-bottom:0.5pt solid #000000;border-right:1.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt;border-bottom:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">69</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:36pt;border-bottom:0.5pt solid #000000;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:55.8pt;border-bottom:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:38pt">66</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:46.7pt;border-bottom:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:85.5pt"><p style="font:9.5pt Times New Roman;margin:0;color:#000000">Total G&amp;A:</p>
</td><td valign="middle" style="width:54pt;border-top:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:37pt">1,740</kbd>&#160;</p>
</td><td valign="middle" style="width:40.5pt;border-top:0.5pt solid #000000;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">17.5</p>
</td><td valign="middle" style="width:49.5pt;border-top:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">2,014</kbd>&#160;</p>
</td><td valign="middle" style="width:40.5pt;border-top:0.5pt solid #000000;border-right:1.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">19.4</p>
</td><td valign="middle" style="width:49.5pt;border-top:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:35pt">3,470</kbd>&#160;</p>
</td><td valign="middle" style="width:36pt;border-top:0.5pt solid #000000;border-right:1pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">17.6</p>
</td><td valign="middle" style="width:55.8pt;border-top:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000"><kbd style="position:absolute;text-align:right;font:9.5pt Times New Roman;width:38pt">4,219</kbd>&#160;</p>
</td><td valign="middle" style="width:46.7pt;border-top:0.5pt solid #000000"><p style="font:9.5pt Times New Roman;margin:0;color:#000000;text-align:center">19.4</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">13</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Total consolidated G&amp;A expenses in 2Q 2025 were $274 lower, and in 1H 2025 were $749 lower than in the same periods in 2024. &#160;The primary cause was lower U.S. litigation expenses - $355 lower in 2Q 2025 compared to 2Q 2024, and $791 lower in 1H 2025 compared to 1H 2024. &#160;Offsetting the significant G&amp;A expense reduction from lower litigation expenses, foreign currency G&amp;A expenses expressed in USD were increased by FX rate differences by $46 in 2Q 2025 and $38 in 1H 2025. &#160;In 2Q 2025, $30 of the $46 higher expense FX impact was the non-cash identifiable intangible asset (IIA) amortization&#8211;UK expense which resulted from the 2011 acquisition of Femcare. The IIA amortization expense in GBP was the same in both periods. Similarly, in 1H 2025, $27 of the $38 higher expense FX impact was the non-cash identifiable intangible asset (IIA) amortization&#8211;UK. As a side note, the Femcare IIA non-cash amortization expense, which has reduced Operating Income approximately $2 million per year since 2011, will be fully amortized in 1Q 2026. Other-US G&amp;A expenses were $46 higher in 2Q 2025 compared to 2Q 2024, and $39 higher in 1H 2025 compared to 1H 2024. The 2Q 2025 $46 increase was due to $34 higher non-cash stock option expense along with increased independent financial auditor fees and other outside services. &#160;The 1H 2025 $39 net higher Other-US G&amp;A expenses were essentially due to $37 higher stock option expense, $24 higher accounting and other outside services, and $12 higher outside director fees offset by $32 lower salaries. &#160;Other G&amp;A expenses in the aggregate were similar in both 2025 and 2024 periods. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The differences in period-to-period R&amp;D expenses were primarily due to the completion of independent validation of material composition of biopharma sensors. Since all R&amp;D in 2025 was carried out in the U.S., there was no FX rate impact. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The impact of differing FX rates in 2025 and 2024 on Operating Expenses expressed in USD was minor. The AUD and CAD were slightly weaker, but the EUR and GBP stronger which helped increase foreign currency Operating Expense when converted to USD by a net $50 in 2Q 2025 and $40 in 1H 2025. The following table summarizes &#8220;constant currency&#8221; Operating Expenses in 2Q and 1H 2025 compared to the same periods in 2024 by OE category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;margin-left:5.4pt"><tr><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0">OE<br/><span style="border-bottom:1px solid #000000">Category</span></p>
</td><td valign="bottom" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2Q 2025<br/><span style="border-bottom:1px solid #000000">const FX</span></p>
</td><td valign="bottom" style="width:11.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:53.9pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="bottom" style="width:13.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:54pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">1H 2025<br/><span style="border-bottom:1px solid #000000">const FX</span></p>
</td><td valign="bottom" style="width:13.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:59.4pt"><p style="font:10pt Times New Roman;margin:0">S&amp;M:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">520</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:53.9pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">546</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">1,022</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">958</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0">G&amp;A:</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">1,694</kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:53.9pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">2,014</kbd>&#160;</p>
</td><td valign="top" style="width:13.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:54pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">3,432</kbd>&#160;</p>
</td><td valign="top" style="width:13.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">4,219</kbd>&#160;</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:59.4pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">R&amp;D:</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">135</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:53.9pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">255</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">290</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">520</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0">Total OE:</p>
</td><td valign="top" style="width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:37pt">2,349</kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:53.9pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">2,815</kbd>&#160;</p>
</td><td valign="top" style="width:13.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:54pt;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">4,744</kbd>&#160;</p>
</td><td valign="top" style="width:13.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:58.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:36pt">5,697</kbd>&#160;</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">e)</kbd><kbd style="margin-left:22.5pt"></kbd>Non-operating expense/ Non-operating income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Non-operating expense includes bank fees and expenses from losses, if applicable, from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms. &#160;Non-operating income includes 1) income from rent of underutilized property, 2) investment income (interest on cash balances), 3) royalties received from licensing the Company&#8217;s technology, and 4) income from gains, if applicable, from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms. Non-operating income or expense can also include gains or losses from the disposition of assets from time to time. Starting in 2024 for UTMD, there was a new excise tax included in Non-operating expenses: a stock repurchase excise tax included in the so-called &#8220;Inflation Reduction Act of 2022&#8221;. After the U.S. Treasury and IRS announced regulations governing the stock repurchase excise tax in 2Q 2024, UTMD began reporting the stock repurchase excise tax in its 2Q 2024 Non-operating expenses based on $9,393 in share repurchases made during 1H 2024. The excise tax on share repurchases in 2Q 2025 and 1H 2025 was $35 and $67 respectively.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net non-operating income is Non-operating income minus Non-operating expense during a particular time period. Net Non-operating income in 2Q 2025 was $640 compared to $773 in 2Q 2024. Net Non-operating income in 1H 2025 was $1,345 compared to $1,688 in 1H 2024. With higher cash balances and higher interest rates in 2024, UTMD received approximately $332 more in 1H interest income compared to 1H 2025. Remeasured foreign currency balances generated about $8 less in net Non-operating income in 1H 2025 compared to 1H 2024. &#160;&#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">f)</kbd><kbd style="margin-left:22.5pt"></kbd>Income Before Income Taxes (EBT)&#160;</p>
<p style="font:11pt Times New Roman;margin:0">Consolidated EBT results from adding net Non-operating income to Operating Income. Consolidated 2Q 2025 EBT was $3,835 (38.5% of sales) compared to $4,211 (40.5% of sales) in 2Q 2024. Consolidated 1H 2025 EBT was $7,694 (39.1% of sales) compared to $9,010 (41.4% of sales) in 1H 2024.  </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">14</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance, as well as its ability to sustain performance during a challenging time. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2025 consolidated EBT excluding the remeasured bank balance currency gain or loss (&#8220;adjusted consolidated EBITDA&#8221;) was $4,671 (46.9% of sales) compared to $4,942 (47.5% of sales) in 2Q 2024. &#160;Adjusted consolidated EBITDA was $9,323 (47.4% of sales) in 1H 2025 compared to $10,489 (48.3% of sales) in 1H 2024. The lower EBITDA in both 2Q and 1H 2025 was due to lower Gross Profit. Adjusted consolidated trailing twelve months&#8217; (TTM) EBITDA was $18,686 as of June 30, 2025. Management&#8217;s beginning of year EBITDA target of $17-$18 million continues to look achievable. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number: &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:432pt;margin-left:5.4pt"><tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2Q 2025</span></p>
</td><td valign="top" style="width:58.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2Q 2024</span></p>
</td><td valign="top" style="width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1H 2025</span></p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1H 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">EBT</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">3,835</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">4,211&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:41pt">7,694</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt">9,010&#160;</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">Depreciation Expense</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">206</kbd>&#160;</p>
</td><td valign="top" style="width:58.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">172&#160;</kbd>&#160;</p>
</td><td valign="top" style="width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:41pt">405</kbd>&#160;</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt">327&#160;</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">Femcare IIA Amortization Expense</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">531</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">501&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:41pt">1,032</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt">1,005&#160;</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:58.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">Other Non-Cash Amortization Expense</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">8</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">8&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:41pt">17</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt">18&#160;</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">Stock Option Compensation Expense</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">86</kbd>&#160;</p>
</td><td valign="top" style="width:58.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">52&#160;</kbd>&#160;</p>
</td><td valign="top" style="width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:41pt">168</kbd>&#160;</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt">130&#160;</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">Interest Expense</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">-</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">-&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:41pt">-</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt">-&#160;</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="width:207pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Remeasured Foreign Currency Balances</p>
</td><td valign="top" style="width:49.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">5</kbd>&#160;</p>
</td><td valign="top" style="width:58.5pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">(2)</kbd>&#160;</p>
</td><td valign="top" style="width:58.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:41pt">7</kbd>&#160;</p>
</td><td valign="top" style="width:58.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt">(1)</kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">UTMD non-US GAAP EBITDA:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:35pt">4,671</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">4,942&#160;</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:41pt">9,323</kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt">10,489&#160;</kbd>&#160;</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">g)</kbd><kbd style="margin-left:22.5pt"></kbd>Net Income &#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net Income is EBT minus a provision for income taxes. &#160;Net Income in 2Q 2025 of $3,048 (30.6% of sales) was 11.7% lower than the Net Income of $3,453 (33.2% of sales) in 2Q 2024. &#160;The $405 lower 2Q Net Income was due to $243 lower Operating Income combined with $133 lower net Non-operating income, and a higher estimated average income tax provision rate. The average consolidated income tax provision rate (as a % of the same period EBT) in 2Q 2025 was 20.5% compared to 18.0% in 2Q 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net Income in 1H 2025 of $6,089 (31.0% of sales) was 17.8% lower than the Net Income of $7,409 (34.1% of sales) in 1H 2024. &#160;The $1,320 lower 1H 2025 Net Income was due to $972 lower Operating Income combined with $343 lower net Non-operating income, and a higher estimated average income tax provision rate. The average consolidated income tax provision rate (as a % of the same period EBT) in 1H 2025 was 20.9% compared to 17.8% in 1H 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. The basic corporate income tax rates in each of the sovereignties were the same as in the prior year. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:9pt"></kbd>h) &#160;&#160;Earnings Per Share (EPS)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EPS are consolidated Net Income divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are &#8220;in the money,&#8221; i.e., have exercise prices below the applicable period&#8217;s weighted average market value). Because the average exercise price of employee and director options was higher than the ending market price of the stock in both 2Q 2025 and 2Q 2024, as well as in 1H 2025 and 1H 2024, the number of shares added as a dilution factor in both years&#8217; 2Q and 1H were zero. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Diluted EPS in 2Q 2025 were $0.939 compared to diluted EPS of $0.978 in 2Q 2024, a 4.0% decrease. Diluted EPS in 1H 2025 were $1.858 compared to diluted EPS of $2.070 in 1H 2024, a 10.3% decrease. The percentage decreases comparing 2Q and 1H 2025 EPS with the prior year&#8217;s same periods were substantially lower than the decreases in Net Income as a result of fewer diluted shares. &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Diluted shares were 3,245,979 in 2Q 2025 compared to 3,531,572 in 2Q 2024. &#160;Diluted shares were 3,277,936 in 1H 2025 compared to 3,579,435 in 1H 2024. The lower diluted shares in both periods of 2025 were the result of shares repurchased during 1H 2025. Because the average exercise price of employee options was higher than the ending market price of the stock in both 2Q 2025 and 2Q 2024, the number of shares added as a dilution factor in both 2Q 2025 and 2Q 2024 were zero. The same was true for both 1H 2025 and 1H 2024. The number of shares used for calculating EPS in both years was higher than period-ending outstanding shares because of a time-weighted calculation of average outstanding shares. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Outstanding shares at the end of 2Q 2025 were 3,215,901 compared to 3,335,156 at the end of calendar year 2024. The difference was due to 119,255 shares repurchased in 1H 2025. Shares repurchased in 2Q 2025 were 64,988 at an average price of $53.67. &#160;Shares repurchased in 1H 2025 were 119,255, at an average price of $56.26. &#160;The total cost of repurchasing shares in 1H 2025 was $6,709 plus a 1% excise tax. Outstanding shares one year earlier were 3,498,902 at the end of 2Q 2024. Outstanding shares at the end of calendar 2023 were 3,629,525. The total cost of repurchasing 421,216 shares in the six calendar quarters since the end of 2023 was $26,676 plus a 1% federal excise tax. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The total number of outstanding unexercised employee and outside director options at June 30, 2025 was 97,685 at an average exercise price of $73.76, including shares awarded but not yet vested. &#160;This compares to 73,497 unexercised option shares at the end of 2Q 2024 at an average exercise price of $77.01/ share, including shares awarded but not vested. No employee options have been awarded in 2025. &#160;Non-qualified option awards totaling 24,600 shares were made to 47 employees and one director in November 2024 at an exercise price of $64.09. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:45pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-36pt">i)</kbd><kbd style="margin-left:-22.5pt"></kbd>Return on Equity (ROE)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">ROE is the portion of Net Income retained by UTMD to internally finance its growth, pay dividends and make share repurchases divided by the average accumulated stockholders&#8217; equity for the applicable time period. &#160;Annualized ROE in 1H 2025 (before stockholder dividends) was 10% compared to 12% 1H 2024. The lower 2025 ROE was due to the 18% decline in 1H 2025 Net Income. Targeting a high ROE of 20% remains a financial objective for UTMD management. &#160;An increase in average stockholders&#8217; equity occurred even after reductions due to paying cash dividends to stockholders and repurchasing shares. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD paid $1,001 ($0.305/share) in dividends to stockholders in 2Q 2025 compared to $1,081 ($0.300/ share) paid in 2Q 2024. The dividends paid to stockholders during 2Q 2025 were 33% of NI. UTMD paid $2,018 ($0.305/share) in dividends to stockholders in 1H 2025 compared to $2,170 ($0.300/ share) paid in 1H 2024. The dividends paid to stockholders during 1H 2025 were 33% of NI. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s closing share price at the end of 2Q 2025 was $56.92 up 1.6% from the closing price of $56.04 at the end of 1Q 2025, and down 7.4% from the closing price of $61.47 at the end of 2024. &#160;The closing share price one year ago at the end of 2Q 2024 was $66.81. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Liquidity and Capital Resources</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">j)</kbd><kbd style="margin-left:22.5pt"></kbd>Cash flows&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $7,337 in 1H 2025 compared to $8,038 in 1H 2024. The $701 lower increase in cash provided by operating activities included $1,320 lower Net Income in 1H 2025 along with a $748 increased use of cash to decrease accrued expenses. The lower contributions to or use of cash were offset by $409 cash provided by lower accounts receivable compared to $351 higher accounts receivable in 1H 2024, and a $466 greater decrease in inventories than in the prior year. &#160; </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Capital expenditures for property and equipment (PP&amp;E) were $235 in 1H 2025 compared to $132 in 1H 2024. The amount invested in 1H 2025 was $171 less than depreciation expense. Depreciation of PP&amp;E was $405 in 1H 2025 compared to $327 in 1H 2024, as new equipment was placed in service for biopharma sensor manufacturing. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD made cash dividend payments to stockholders of $2,018 in 1H 2025 compared to $2,170 in 1H 2024. &#160;The difference was due to 1.7% higher dividends paid per share than in the previous year, offset by 8.5% lower number of shares due to share repurchases. &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">16</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">In 1H 2025, there were no employee or director option exercises. &#160;In 1H 2024, UTMD received $390 and issued 7,592 shares of its stock upon the exercise of employee stock options. Option exercises in 1H 2024 were at an average price of $51.39 per share.  </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans. The Company intends to utilize cash not needed to support normal operations in one or a combination of the following: &#160;1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD&#8217;s existing infrastructure. &#160;If there are no better strategic uses for UTMD&#8217;s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">k)</kbd><kbd style="margin-left:22.5pt"></kbd>Assets and Liabilities&#160;</p>
<p style="font:10pt Times New Roman;margin:0">At June 30, 2025, UTMD&#8217;s cash and investments decreased $797 to $82,179 from $82,976 at the end of 2024 as a result of using $8,727 in cash repurchasing UTMD stock and paying shareholder dividends, offset by 1H 2025 Net Income of $6,089. &#160;The $1,841 higher cash difference resulted primarily from $579 lower inventories and $463 lower accounts receivable. At June 30, 2025, net Intangible Assets were 13.4% of total consolidated assets compared to 13.5% on December 31, 2024 despite Femcare intangible assets in the UK being valued 9.6% higher as a result of a stronger GBP and total assets being 1% lower. UTMD&#8217;s strong 41.9 current ratio at June 30, 2025 was higher than the 25.6 current ratio at December 31, 2024 despite 2% lower current assets, as a result of a 36% decline in accrued liabilities and the final elimination of repatriation tax payable under the 2017 TCJA. The average age of trade receivables was 33 days from date of invoice at June 30, 2025 compared to 40 days at December 31, 2024 based on the most recent calendar quarter of sales. Average inventory turns improved to 2.1 in 2Q 2025 compared to 2.0 for the last quarter of 2024 due to a $579 inventory reduction despite lower sales activity. &#160;Both inventory turn numbers after extra safety stocks of raw materials acquired during the COVID pandemic are below management targets.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">June 30, 2025 total consolidated assets were $120,802, a decrease of $1,736 from December 31, 2024. Current assets were $1,956 lower than at December 31, 2024 because of the $797 decrease in cash, $463 decrease in receivables and $579 decrease in inventories. &#160;Net fixed assets (property, plant and equipment) in Utah increased $10 as new acquisitions slightly exceeded depreciation. OUS subsidiary net fixed assets increased $485 despite depreciation which exceeded new acquisitions because of higher FX rates for foreign currency-valued assets in Ireland, the UK, Australia and Canada. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">For clarity, the net book value of consolidated property, plant and equipment increased $495 at June 30, 2025 from the end of 2024 due to the net effect on OUS asset values of period-ending changed FX rates, $235 in new asset purchases minus $405 in depreciation. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">June 30, 2025 net intangible assets (goodwill plus other intangible assets) declined $275 from the end of 2024 as a result of $1,048 in amortization and a 9.6% stronger GBP/USD FX rate on UK intangible asset balances. At June 30, 2025, net intangible assets including goodwill were 13% of total consolidated assets compared to 13% at year-end 2024 and 13% at June 30, 2024. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Working capital (current assets minus current liabilities) was $92,120 at June 30, 2025 compared to $92,574 at December 31, 2024. Cash balances were 89% of the June 30, 2025 working capital. Current assets at June 30, 2025 compared to December 31, 2024 were $1,956 lower as the result of the $797 decrease in cash combined with a $579 decrease in inventories and a $463 decrease in total receivables. Current liabilities were $1,502 lower at June 30, 2025 compared to December 31, 2024 as the result of a $845 decrease in accrued liabilities and elimination of a $698 remaining repatriation tax payable. &#160;The $845 lower accrued liabilities resulted mainly from a $405 lower estimated income taxes liability, a $284 lower employee profit-sharing bonus accrual at mid-year 2025 compared to the end-of-year 2024 accrual and a $127 lower excise tax liability for share repurchases at mid-year 2025 compared to the end-of-year 2024. Management believes that UTMD&#8217;s working capital remains more than sufficient to meet operating needs, new capital expenditures, projected cash dividend payments to stockholders and continued share repurchases.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">June 30, 2025 total consolidated liabilities were $3,269, a decline of $1,842 from December 31, 2024. Current liabilities were $1,502 lower than at December 31, 2024. Long term liabilities were $339 lower, including the deferred tax liability balance resulting from non-tax deductible Femcare IIA amortization expense being $215 lower. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">17</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The deferred tax liability balance for Femcare IIA ($9,084 on the date of the acquisition), was $389 at June 30, 2025 compared to $604 at December 31, 2024 and $860 at June 30, 2024. Reduction of the deferred tax liability occurs as the book/tax difference of amortization is eliminated over the remaining useful life of the Femcare IIA, i.e. as Femcare pays its taxes in the UK without the benefit of a deduction for IIA amortization expense. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s total debt ratio (total liabilities/ total assets) at June 30, 2025 was 2.7%, at December 31, 2024 was 4.2%, and at June 30, 2024 was 4.6%. &#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:9pt"></kbd>l) Management's Outlook&#160;</p>
<p style="font:10pt Times New Roman;margin:0">As outlined in its December 31, 2024 SEC 10-K report, UTMD&#8217;s plan for 2025 remains to</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:45pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-19.5pt">1)</kbd>exploit its pre-qualified status to market a line of high-pressure process control transducer configurations directly to biopharmaceutical manufacturers;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:45pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-19.5pt">2)</kbd>continue to leverage OUS distribution and manufacturing synergies by further integrating capabilities and resources in multinational operations; &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:45pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-19.5pt">3)</kbd>focus on defending the proven safety and effectiveness of the Filshie Clip System in the U.S.;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:45pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-19.5pt">4)</kbd>introduce additional products helpful to clinicians through product development; &#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:45pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-19.5pt">5)</kbd>continue to achieve excellent overall financial operating performance despite a contraction in revenues; &#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:45pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-19.5pt">6)</kbd>utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/ when the UTMD share price seems undervalued; and&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:45pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-19.5pt">7)</kbd>remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions on small, innovative companies. &#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:-27pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">m)</kbd><kbd style="margin-left:22.5pt"></kbd>Accounting Policy Changes&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">None.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Forward-Looking Information. &#160;This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. &#160;When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221; and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. &#160;Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. &#160;Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected or intended. &#160;Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. &#160;Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">18</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a8"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 3.</b> <b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and in Canada denominated in the Canadian Dollar (CAD). The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. &#160;The exchange rates were .8496, .9661 and .9336 EUR per USD as of June 30, 2025, December 31, 2024 and June 30, 2024, respectively. &#160;Exchange rates were .7288, .7987 and .7913 GBP per USD as of June 30, 2025, December 31, 2024 and June 30, 2024, respectively. &#160;Exchange rates were 1.5216, 1.6172 and 1.4983 AUD per USD on June 30, 2025, December 31, 2024 and June 30, 2024, respectively. &#160;Exchange rates were 1.3620, 1.4403, and 1.3686 CAD per USD on June 30, 2025, December 31, 2024 and June 30, 2024, respectively. UTMD manages its foreign currency risk without separate hedging transactions by either invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur and/or by optimizing global account structures through liquidity management accounts.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a9"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 4. Controls and Procedures</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The Company&#8217;s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of June 30, 2025. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of June 30, 2025, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the six months ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal controls over financial reporting. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">19</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">PART II - OTHER INFORMATION</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a10"></a><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"><b>Item 1.</b></kbd><kbd style="margin-left:45pt"></kbd><b>Legal Proceedings</b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD is a party from time to time in litigation incidental to its business. Presently, except for Filshie clip product liability lawsuits still in discovery, there is no litigation. The Company does not expect the outcome of the Filshie clip litigation will be material to consolidated financial results.  </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a11"></a><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"><b>Item 1A.</b></kbd><kbd style="margin-left:37.8pt"></kbd><b> &#160;Risk Factors &#160;</b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a12"></a><p style="font:10pt Times New Roman;margin:0"><span style="color:#333333">In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in UTMD&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, which could materially affect its business, financial condition or future results. &#160;The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. &#160;Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company&#8217;s business, financial condition and/or operating results.</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"><b>Item 2.</b></kbd><kbd style="margin-left:31.5pt"></kbd><b> Unregistered Sales of Equity Securities and Use of Proceeds</b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table details purchases by UTMD of its own securities during 2Q 2025.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;width:481.05pt"><tr style="height:107.7pt"><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Period</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(a)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased (1)</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(b)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Average price paid per share (1)</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(c)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased as part of publicly announced plans or programs (1)</p>
</td><td valign="top" style="width:96.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(d)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (1)</p>
</td></tr>
<tr style="height:12.8pt"><td valign="top" style="background-color:#D3F0FE;width:96.2pt"><p style="font:10pt Times New Roman;margin:0">04/01/25 &#8211;&#160;04/30/25</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">32,679</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">53.67</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:13.55pt"><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0">05/01/25 &#8211;&#160;05/31/25</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,053</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">53.45</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:13.55pt"><td valign="top" style="background-color:#D3F0FE;width:96.2pt"><p style="font:10pt Times New Roman;margin:0">06/01/25 &#8211;&#160;06/30/25</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">31,256</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">53.68</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:12.8pt"><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">64,988</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">53.67</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:8pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:-18pt">1)</kbd>None of the shares were purchased as part of a publicly announced plan and all were purchased on the open market.&#160;</p>
<p style="font:8pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:-18pt">2)</kbd>The total number of shares repurchased to-date in 2025 through August 11 was 129,433 at an average cost of $56.21/ share, approximately 4% of year-end 2024 outstanding shares.&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The frequency of UTMD&#8217;s open market share repurchases depends on the availability of sellers and the price of the stock. The board of directors has not established an expiration date or a maximum dollar or share limit for UTMD&#8217;s continuing and long-term pattern of opportunistic open market share repurchases since 1992. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a13"></a><p style="font:10pt Times New Roman;margin:0">The purpose of UTMD&#8217;s ongoing share repurchases is to maximize the value of the Company for its continuing stockholders, and maximize its return on stockholder equity by employing excess cash generated by effectively managing its business<span style="color:#FF0000">. </span>UTMD does not intend to repurchase shares that would result in terminating its Nasdaq Global Market listing.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">20</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><b>Item 6. &#160;Exhibits </b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr style="height:14.3pt"><td valign="bottom" style="width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Exhibit #</span></p>
</td><td valign="bottom" style="width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">SEC <span style="border-bottom:1px solid #000000">Reference #</span></p>
</td><td valign="bottom" style="width:359.9pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Title of Document</span></p>
</td></tr>
<tr style="height:3.55pt"><td valign="top" style="width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:359.9pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:23.9pt"><td valign="top" style="background-color:#D3F0FE;width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31.1</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31</p>
</td><td valign="top" style="background-color:#D3F0FE;width:359.9pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z1.htm" style="text-decoration:none">Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:23.15pt"><td valign="top" style="width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31.2</p>
</td><td valign="top" style="width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31</p>
</td><td valign="top" style="width:359.9pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z1.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:23.9pt"><td valign="top" style="background-color:#D3F0FE;width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32.1</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32</p>
</td><td valign="top" style="background-color:#D3F0FE;width:359.9pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z1.htm" style="text-decoration:none">Certification of CEO pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:23.15pt"><td valign="top" style="width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32.2</p>
</td><td valign="top" style="width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32</p>
</td><td valign="top" style="width:359.9pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z2.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:11.95pt"><td valign="top" style="background-color:#D3F0FE;width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.ins</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101 ins</p>
</td><td valign="top" style="background-color:#D3F0FE;width:359.9pt"><p style="font:10pt Times New Roman;margin:0">XBRL Instance</p>
</td></tr>
<tr style="height:11.2pt"><td valign="top" style="width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.sch</p>
</td><td valign="top" style="width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.sch</p>
</td><td valign="top" style="width:359.9pt"><p style="font:10pt Times New Roman;margin:0">XBRL Schema</p>
</td></tr>
<tr style="height:11.95pt"><td valign="top" style="background-color:#D3F0FE;width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.cal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.cal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:359.9pt"><p style="font:10pt Times New Roman;margin:0">XBRL Calculation</p>
</td></tr>
<tr style="height:11.95pt"><td valign="top" style="width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.def</p>
</td><td valign="top" style="width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.def</p>
</td><td valign="top" style="width:359.9pt"><p style="font:10pt Times New Roman;margin:0">XBRL Definition</p>
</td></tr>
<tr style="height:11.2pt"><td valign="top" style="background-color:#D3F0FE;width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.lab</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.lab</p>
</td><td valign="top" style="background-color:#D3F0FE;width:359.9pt"><p style="font:10pt Times New Roman;margin:0">XBRL Label</p>
</td></tr>
<tr style="height:11.95pt"><td valign="top" style="width:50.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.pre</p>
</td><td valign="top" style="width:63.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.pre</p>
</td><td valign="top" style="width:359.9pt"><p style="font:10pt Times New Roman;margin:0">XBRL Presentation</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<a id="a14"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">SIGNATURES</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:28.8pt"></kbd>Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd>REGISTRANT&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;8/12/25 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Kevin L. Cornwell &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Kevin L. Cornwell&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>CEO&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;8/12/25 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Brian L. Koopman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Brian L. Koopman&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:219.1pt"></kbd>Principal Financial Officer&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">21</p>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>utmd_ex31z1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'><B>Exhibit 31.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF CEO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Kevin L. Cornwell, certify that:</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Date: August 12, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>utmd_ex31z2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>I, Brian L. Koopman, certify that:</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Date: August 12, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Brian L. Koopman &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>utmd_ex32z1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 32.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-73.8pt;margin-left:73.8pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt Times New Roman;margin:0'>August 12, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. &nbsp;</I><BR></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>utmd_ex32z2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P style='font:10pt Times New Roman;margin:0'><KBD style=margin-left:403.2pt></KBD><B>Exhibit 32.2</B>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<P style='font:10pt Times New Roman;margin:0'>August 12, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. &nbsp;</I></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>utmd-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_Goodwill' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermDebtNoncurrent' xlink:label='us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OtherLongTermDebtNoncurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability' xlink:label='us-gaap_OperatingLeaseLiability'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OperatingLeaseLiability' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_Depreciation' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' use='optional' order='8.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>utmd-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure1BasisOfPresentation" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure1BasisOfPresentation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure1BasisOfPresentation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure2RecentAccountingStandards" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure2RecentAccountingStandards"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure2RecentAccountingStandards"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure3Inventories" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure3Inventories"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure3Inventories"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensation" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure4StockBasedCompensation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure5WarrantyReserve" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure5WarrantyReserve"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure5WarrantyReserve"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognition" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure6RevenueRecognition"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognition"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShare" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure7EarningsPerShare"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShare"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformation" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure8SegmentInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure9SubsequentEvents" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure9SubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure9SubsequentEvents"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure4StockBasedCompensationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensationDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis' xlink:label='srt_StatementScenarioAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementScenarioAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementScenarioAxis' xlink:to='srt_ScenarioUnspecifiedDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementScenarioAxis' xlink:to='srt_ScenarioUnspecifiedDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_SingleOperatingSegmentMember' xlink:label='fil_SingleOperatingSegmentMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ScenarioUnspecifiedDomain' xlink:to='fil_SingleOperatingSegmentMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_StandardCostOfSales' xlink:label='fil_StandardCostOfSales'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StandardCostOfSales' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_OtherCostOfSales' xlink:label='fil_OtherCostOfSales'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OtherCostOfSales' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_GrossProfitMargin' xlink:label='fil_GrossProfitMargin'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrossProfitMargin' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense' xlink:label='us-gaap_SellingAndMarketingExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SellingAndMarketingExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_LitigationExpense' xlink:label='fil_LitigationExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_LitigationExpense' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherSellingGeneralAndAdministrativeExpense' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_OperatingIncomeMargin' xlink:label='fil_OperatingIncomeMargin'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OperatingIncomeMargin' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInterestAndDividendIncome' xlink:label='us-gaap_OtherInterestAndDividendIncome'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherInterestAndDividendIncome' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet' xlink:label='us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherOperatingIncomeExpenseNet' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='17.0'/>
	</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>utmd-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:to='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, Raw Materials, Gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet' xlink:label='us-gaap_InterestPaidNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaidNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaidNet' xlink:to='lab_us-gaap_InterestPaidNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>OutsideUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the OutsideUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutsideUsMember' xlink:to='lab_fil_OutsideUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(9) Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(7) Earnings Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareTextBlock' xlink:to='lab_us-gaap_EarningsPerShareTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for (recovery of) losses on accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Operating income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='lab_us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Goodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Goodwill</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Goodwill' xlink:to='lab_us-gaap_Goodwill'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_GrossProfitMargin' xlink:label='fil_GrossProfitMargin'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossProfitMargin' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross Profit Margin</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossProfitMargin' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the percentage value of Gross Profit Margin, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrossProfitMargin' xlink:to='lab_fil_GrossProfitMargin'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Blood Pressure Monitoring and Accessories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BloodPressureMonitoringAndAccessoriesMember' xlink:to='lab_fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Selling, General and Administrative Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductOrServiceAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductOrServiceAxis' xlink:to='lab_srt_ProductOrServiceAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(5) Warranty Reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyDisclosureTextBlock' xlink:to='lab_us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SupplementalCashFlowInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='lab_us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:to='lab_us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AmortizationOfIntangibleAssets' xlink:to='lab_us-gaap_AmortizationOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details {4}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='lab_us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Security Exchange Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:label='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule Of Global Revenues By Product Category</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Schedule of Global Revenues by Product Category.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:to='lab_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockOptionPlanExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockOptionPlanExpense' xlink:to='lab_us-gaap_StockOptionPlanExpense'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInterestAndDividendIncome' xlink:label='us-gaap_OtherInterestAndDividendIncome'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherInterestAndDividendIncome' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Interest and Dividend Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherInterestAndDividendIncome' xlink:to='lab_us-gaap_OtherInterestAndDividendIncome'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DomesticUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the DomesticUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DomesticUsMember' xlink:to='lab_fil_DomesticUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total adjustments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='lab_us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from sale of property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:to='lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DividendsCommonStockCash' xlink:to='lab_us-gaap_DividendsCommonStockCash'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet' xlink:label='us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherOperatingIncomeExpenseNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Operating Income (Expense), Net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherOperatingIncomeExpenseNet' xlink:to='lab_us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Inventory, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(6) Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Foreign currency translation net of taxes of $0 in all periods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense' xlink:label='us-gaap_SellingAndMarketingExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingAndMarketingExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling and Marketing Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingAndMarketingExpense' xlink:to='lab_us-gaap_SellingAndMarketingExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, Work in Process, Gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(1) Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-based compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='lab_us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsReceivableNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts &amp; other receivables, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsReceivableNetCurrent' xlink:to='lab_us-gaap_AccountsReceivableNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_OtherCostOfSales' xlink:label='fil_OtherCostOfSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OtherCostOfSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other cost of sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OtherCostOfSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Other cost of sales, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OtherCostOfSales' xlink:to='lab_fil_OtherCostOfSales'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obstetrics</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Obstetrics, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ObstetricsMember' xlink:to='lab_fil_ObstetricsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_SegmentGeographicalDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_SegmentGeographicalDomain' xlink:to='lab_srt_SegmentGeographicalDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock' xlink:label='us-gaap_SegmentReportingDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SegmentReportingDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(8) Segment Information</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SegmentReportingDisclosureTextBlock' xlink:to='lab_us-gaap_SegmentReportingDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(3) Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaid' xlink:to='lab_us-gaap_IncomeTaxesPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization of Right-of-Use Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2025, 3,216 shares and December 31, 2024, 3,335 shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability - Femcare IIA</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableCurrent' xlink:to='lab_us-gaap_AccountsPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_Security12bTitle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Title of 12(b) Security</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_Security12bTitle' xlink:to='lab_dei_Security12bTitle'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentTransitionReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Transition Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentTransitionReport' xlink:to='lab_dei_DocumentTransitionReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ScenarioUnspecifiedDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Scenario</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ScenarioUnspecifiedDomain' xlink:to='lab_srt_ScenarioUnspecifiedDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, Finished Goods, Net of Reserves</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:to='lab_us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash at end of period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of common stock - options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:to='lab_us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares outstanding - diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherNonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherNonoperatingIncomeExpense' xlink:to='lab_us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability' xlink:label='us-gaap_OperatingLeaseLiability'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseLiability' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating lease liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseLiability' xlink:to='lab_us-gaap_OperatingLeaseLiability'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Tax Identification Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_LitigationExpense' xlink:label='fil_LitigationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LitigationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Litigation Expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LitigationExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Litigation Expense, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LitigationExpense' xlink:to='lab_fil_LitigationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductsAndServicesDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductsAndServicesDomain' xlink:to='lab_srt_ProductsAndServicesDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of exchange rate changes on cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:to='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details {3}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='lab_us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Sales, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:to='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalCommonStock' xlink:to='lab_us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:to='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermDebtNoncurrent' xlink:label='us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLongTermDebtNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other long term liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLongTermDebtNoncurrent' xlink:to='lab_us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_OperatingIncomeMargin' xlink:label='fil_OperatingIncomeMargin'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OperatingIncomeMargin' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Income Margin</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OperatingIncomeMargin' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the percentage value of Operating Income Margin, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OperatingIncomeMargin' xlink:to='lab_fil_OperatingIncomeMargin'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Neonatal</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Neonatal, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NeonatalMember' xlink:to='lab_fil_NeonatalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementGeographicalAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementGeographicalAxis' xlink:to='lab_srt_StatementGeographicalAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(4) Stock-Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:to='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(2) Recent Accounting Standards</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquireIntangibleAssets' xlink:to='lab_us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfGoodsAndServicesSold' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of goods sold</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfGoodsAndServicesSold' xlink:to='lab_us-gaap_CostOfGoodsAndServicesSold'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentQuarterlyReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Quarterly Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentQuarterlyReport' xlink:to='lab_dei_DocumentQuarterlyReport'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gynecology/Electrosurgery/Urology</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GynecologyElectrosurgeryUrologyMember' xlink:to='lab_fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:label='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Segment Reporting Information, by Segment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:to='lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payment of dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payment of dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsOfDividends' xlink:to='lab_us-gaap_PaymentsOfDividends'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares outstanding - basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Weighted average shares, basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsGross' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash &amp; investments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_StandardCostOfSales' xlink:label='fil_StandardCostOfSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_StandardCostOfSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Standard cost of sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_StandardCostOfSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Standard cost of sales, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_StandardCostOfSales' xlink:to='lab_fil_StandardCostOfSales'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis' xlink:label='srt_StatementScenarioAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementScenarioAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Scenario [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementScenarioAxis' xlink:to='lab_srt_StatementScenarioAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax benefit attributable to exercise of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:to='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research &amp; development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling, general and administrative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_SingleOperatingSegmentMember' xlink:label='fil_SingleOperatingSegmentMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SingleOperatingSegmentMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Single Operating Segment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SingleOperatingSegmentMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Single Operating Segment, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SingleOperatingSegmentMember' xlink:to='lab_fil_SingleOperatingSegmentMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeMember' xlink:to='lab_us-gaap_ComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>utmd-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentQuarterlyReport' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentTransitionReport' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_Security12bTitle' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='33.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='34.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Goodwill' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Assets' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermDebtNoncurrent' xlink:label='us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_OtherLongTermDebtNoncurrent' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability' xlink:label='us-gaap_OperatingLeaseLiability'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_OperatingLeaseLiability' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_SupplementalCashFlowInformationAbstract' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_IncomeTaxesPaid' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet' xlink:label='us-gaap_InterestPaidNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_InterestPaidNet' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure1BasisOfPresentation" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure1BasisOfPresentation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure1BasisOfPresentation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure2RecentAccountingStandards" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure2RecentAccountingStandards"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure2RecentAccountingStandards">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure3Inventories" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure3Inventories"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure3Inventories">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensation" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure4StockBasedCompensation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure5WarrantyReserve" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure5WarrantyReserve"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure5WarrantyReserve">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ProductWarrantyDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognition" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure6RevenueRecognition"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognition">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShare" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure7EarningsPerShare"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShare">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_EarningsPerShareTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformation" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure8SegmentInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock' xlink:label='us-gaap_SegmentReportingDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SegmentReportingDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure9SubsequentEvents" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure9SubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure9SubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:label='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:label='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure4StockBasedCompensationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensationDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" xlink:type="simple" xlink:href="utmd-20250630.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis' xlink:label='srt_StatementScenarioAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementScenarioAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementScenarioAxis' xlink:to='srt_ScenarioUnspecifiedDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_SingleOperatingSegmentMember' xlink:label='fil_SingleOperatingSegmentMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementScenarioAxis' xlink:to='fil_SingleOperatingSegmentMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_StandardCostOfSales' xlink:label='fil_StandardCostOfSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StandardCostOfSales' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_OtherCostOfSales' xlink:label='fil_OtherCostOfSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OtherCostOfSales' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_GrossProfitMargin' xlink:label='fil_GrossProfitMargin'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrossProfitMargin' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense' xlink:label='us-gaap_SellingAndMarketingExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SellingAndMarketingExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_LitigationExpense' xlink:label='fil_LitigationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_LitigationExpense' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherSellingGeneralAndAdministrativeExpense' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250630.xsd#fil_OperatingIncomeMargin' xlink:label='fil_OperatingIncomeMargin'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OperatingIncomeMargin' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInterestAndDividendIncome' xlink:label='us-gaap_OtherInterestAndDividendIncome'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherInterestAndDividendIncome' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet' xlink:label='us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherOperatingIncomeExpenseNet' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='17.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>utmd-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA34KPNR]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://www.utahmed.com/20250630' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://www.utahmed.com/20250630' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:dei='http://xbrl.sec.gov/dei/2025' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2024-01-31' xmlns:srt='http://fasb.org/srt/2025' xmlns:us-gaap='http://fasb.org/us-gaap/2025'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails" id="idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails">
				<link:definition>000240 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" id="idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow">
				<link:definition>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensationDetails" id="idr_Disclosure4StockBasedCompensationDetails">
				<link:definition>000220 - Disclosure - (4) Stock-Based Compensation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensation" id="idr_Disclosure4StockBasedCompensation">
				<link:definition>000110 - Disclosure - (4) Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables" id="idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables">
				<link:definition>000170 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShare" id="idr_Disclosure7EarningsPerShare">
				<link:definition>000140 - Disclosure - (7) Earnings Per Share</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" id="idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails">
				<link:definition>000250 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformation" id="idr_Disclosure8SegmentInformation">
				<link:definition>000150 - Disclosure - (8) Segment Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure9SubsequentEvents" id="idr_Disclosure9SubsequentEvents">
				<link:definition>000160 - Disclosure - (9) Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognition" id="idr_Disclosure6RevenueRecognition">
				<link:definition>000130 - Disclosure - (6) Revenue Recognition</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical">
				<link:definition>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure3Inventories" id="idr_Disclosure3Inventories">
				<link:definition>000100 - Disclosure - (3) Inventories</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical">
				<link:definition>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" id="idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables">
				<link:definition>000200 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure2RecentAccountingStandards" id="idr_Disclosure2RecentAccountingStandards">
				<link:definition>000090 - Disclosure - (2) Recent Accounting Standards</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome">
				<link:definition>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables" id="idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables">
				<link:definition>000180 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets">
				<link:definition>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity">
				<link:definition>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure1BasisOfPresentation" id="idr_Disclosure1BasisOfPresentation">
				<link:definition>000080 - Disclosure - (1) Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables" id="idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables">
				<link:definition>000190 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails" id="idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails">
				<link:definition>000230 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails" id="idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails">
				<link:definition>000210 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250630/role/idr_Disclosure5WarrantyReserve" id="idr_Disclosure5WarrantyReserve">
				<link:definition>000120 - Disclosure - (5) Warranty Reserve</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2024-01-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2024-01-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2025/dei-2025.xsd' namespace='http://xbrl.sec.gov/dei/2025'/>
	<import schemaLocation='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd' namespace='http://fasb.org/srt/2025'/>
	<import schemaLocation='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd' namespace='http://fasb.org/us-gaap/2025'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DomesticUsMember' name='DomesticUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OutsideUsMember' name='OutsideUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ObstetricsMember' name='ObstetricsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NeonatalMember' name='NeonatalMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GynecologyElectrosurgeryUrologyMember' name='GynecologyElectrosurgeryUrologyMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BloodPressureMonitoringAndAccessoriesMember' name='BloodPressureMonitoringAndAccessoriesMember'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_StandardCostOfSales' name='StandardCostOfSales'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_OtherCostOfSales' name='OtherCostOfSales'/>
	<element nillable='true' type='dtr-types:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GrossProfitMargin' name='GrossProfitMargin'/>
	<element nillable='true' type='dtr-types:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OperatingIncomeMargin' name='OperatingIncomeMargin'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SingleOperatingSegmentMember' name='SingleOperatingSegmentMember'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_LitigationExpense' name='LitigationExpense'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
	<element nillable='true' type='dtr-types:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' name='ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000706698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0342734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,205,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; investments</a></td>
<td class="nump">$ 82,179<span></span>
</td>
<td class="nump">$ 82,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts &amp; other receivables, net</a></td>
<td class="nump">3,632<span></span>
</td>
<td class="nump">4,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">8,233<span></span>
</td>
<td class="nump">8,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">94,375<span></span>
</td>
<td class="nump">96,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,257<span></span>
</td>
<td class="nump">9,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">14,193<span></span>
</td>
<td class="nump">13,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangible assets</a></td>
<td class="nump">56,636<span></span>
</td>
<td class="nump">53,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets - accumulated amortization</a></td>
<td class="num">(54,659)<span></span>
</td>
<td class="num">(50,907)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">1,977<span></span>
</td>
<td class="nump">2,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">120,802<span></span>
</td>
<td class="nump">122,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,254<span></span>
</td>
<td class="nump">3,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability - Femcare IIA</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,269<span></span>
</td>
<td class="nump">5,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2025, 3,216 shares and December 31, 2024, 3,335 shares</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(9,362)<span></span>
</td>
<td class="num">(11,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">126,863<span></span>
</td>
<td class="nump">129,302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">117,533<span></span>
</td>
<td class="nump">117,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 120,802<span></span>
</td>
<td class="nump">$ 122,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Details {1}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,216<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">3,216<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Details {2}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 9,953<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="nump">$ 19,663<span></span>
</td>
<td class="nump">$ 21,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,358<span></span>
</td>
<td class="nump">4,147<span></span>
</td>
<td class="nump">8,530<span></span>
</td>
<td class="nump">8,722<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,595<span></span>
</td>
<td class="nump">6,253<span></span>
</td>
<td class="nump">11,133<span></span>
</td>
<td class="nump">13,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,264<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">4,495<span></span>
</td>
<td class="nump">5,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
<td class="nump">4,784<span></span>
</td>
<td class="nump">5,697<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">3,196<span></span>
</td>
<td class="nump">3,438<span></span>
</td>
<td class="nump">6,349<span></span>
</td>
<td class="nump">7,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">3,836<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">7,694<span></span>
</td>
<td class="nump">9,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">788<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,048<span></span>
</td>
<td class="nump">$ 3,453<span></span>
</td>
<td class="nump">$ 6,089<span></span>
</td>
<td class="nump">$ 7,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares outstanding - basic</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">3,278<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding - diluted</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">3,278<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation net of taxes of $0 in all periods</a></td>
<td class="nump">$ 1,828<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="nump">$ 2,546<span></span>
</td>
<td class="num">$ (664)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 4,876<span></span>
</td>
<td class="nump">$ 3,420<span></span>
</td>
<td class="nump">$ 8,635<span></span>
</td>
<td class="nump">$ 6,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Details {2}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 593<span></span>
</td>
<td class="num">$ (10,658)<span></span>
</td>
<td class="nump">$ 138,341<span></span>
</td>
<td class="nump">$ 128,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions', window );">Common stock received and retired upon exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,221)<span></span>
</td>
<td class="num">(2,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,289)<span></span>
</td>
<td class="nump">138,995<span></span>
</td>
<td class="nump">127,742<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="num">(10,658)<span></span>
</td>
<td class="nump">138,341<span></span>
</td>
<td class="nump">128,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,322)<span></span>
</td>
<td class="nump">135,339<span></span>
</td>
<td class="nump">124,052<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,289)<span></span>
</td>
<td class="nump">138,995<span></span>
</td>
<td class="nump">127,742<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions', window );">Common stock received and retired upon exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(346)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,056)<span></span>
</td>
<td class="num">(6,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,052)<span></span>
</td>
<td class="num">(1,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,453<span></span>
</td>
<td class="nump">3,453<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,322)<span></span>
</td>
<td class="nump">135,339<span></span>
</td>
<td class="nump">124,052<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,908)<span></span>
</td>
<td class="nump">129,302<span></span>
</td>
<td class="nump">117,427<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">3,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,138)<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">718<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,041<span></span>
</td>
<td class="nump">3,041<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2025</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,190)<span></span>
</td>
<td class="nump">128,204<span></span>
</td>
<td class="nump">117,047<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,908)<span></span>
</td>
<td class="nump">129,302<span></span>
</td>
<td class="nump">117,427<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">3,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,089<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2025</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,362)<span></span>
</td>
<td class="nump">126,862<span></span>
</td>
<td class="nump">117,533<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2025</a></td>
<td class="nump">3,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2025</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,190)<span></span>
</td>
<td class="nump">128,204<span></span>
</td>
<td class="nump">117,047<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,402)<span></span>
</td>
<td class="num">(3,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(988)<span></span>
</td>
<td class="num">(988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,048<span></span>
</td>
<td class="nump">3,048<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2025</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (9,362)<span></span>
</td>
<td class="nump">$ 126,862<span></span>
</td>
<td class="nump">$ 117,533<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2025</a></td>
<td class="nump">3,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 6,089<span></span>
</td>
<td class="nump">$ 7,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for (recovery of) losses on accounts receivable</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of Right-of-Use Assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit attributable to exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets', window );">Accounts receivable and other receivables</a></td>
<td class="nump">409<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,531)<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">7,337<span></span>
</td>
<td class="nump">8,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock - options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchased and retired</a></td>
<td class="num">(6,708)<span></span>
</td>
<td class="num">(9,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(2,018)<span></span>
</td>
<td class="num">(2,170)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(8,726)<span></span>
</td>
<td class="num">(11,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">827<span></span>
</td>
<td class="num">(404)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="num">(797)<span></span>
</td>
<td class="num">(3,649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">82,976<span></span>
</td>
<td class="nump">92,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">82,179<span></span>
</td>
<td class="nump">89,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income); loss (gain); increase (decrease) in liability and (increase) decrease in asset used in operating activity; and cash inflow (outflow) from operating activity, classified as other; in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables, and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(1) Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">(1) Basis of Presentation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(1)</kbd><kbd style="margin-left:19.8pt"></kbd>The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2024. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(2) Recent Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">(2) Recent Accounting Standards</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. &#160;ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting AUS 2023-09.</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. &#160;ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting ASU 2024-03. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(3) Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">(3) Inventories</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(3)</kbd><kbd style="margin-left:19.8pt"></kbd>Inventories at June 30, 2025 and December 31, 2024 consisted of the following:&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;margin-left:9.9pt"><tr style="height:9.45pt"><td style="width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:88.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td style="width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:104.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31,</p>
</td></tr>
<tr style="height:9.45pt"><td style="width:119.75pt" valign="top"></td><td style="width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:88.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:104.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:9.45pt"><td style="background-color:#D3F0FE;width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#D3F0FE;width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:88.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt">971</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:104.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt">1,913</kbd>&#160;</p>
</td></tr>
<tr style="height:9.45pt"><td style="width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:88.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt">1,407</kbd>&#160;</p>
</td><td style="width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:104.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt">1,414</kbd>&#160;</p>
</td></tr>
<tr style="height:9.45pt"><td style="background-color:#D3F0FE;width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#D3F0FE;width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:88.1pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt">5,855</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:104.65pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt">5,485</kbd>&#160;</p>
</td></tr>
<tr style="height:9.45pt"><td style="width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total </p>
</td><td style="width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:88.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt">8,233</kbd>&#160;</p>
</td><td style="width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:104.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt">8,812</kbd>&#160;</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(4) Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">(4) Stock-Based Compensation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(4)</kbd><kbd style="margin-left:18pt"></kbd>Stock-Based Compensation.  At June 30, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended June 30, 2025 and 2024, the Company recognized $86 and $52, respectively, in stock-based compensation expense. &#160;In the six months ended June 30, 2025 and 2024, the Company recognized $168 and $131, respectively, in stock-based compensation expense.&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(5) Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">(5) Warranty Reserve</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(5) </kbd><kbd style="margin-left:18pt"></kbd>Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024 or June 30, 2025. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(6) Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">(6) Revenue Recognition</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(6) &#160;Global 2Q 2025 revenues (USD) by product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">818</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">207</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,025</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,421</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,386</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,807</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,737</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">365</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,102</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">889</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,130</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:48.35pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,019</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,865</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,088</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,953</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 1H 2025 revenues (USD) by product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,650</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">400</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,050</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,751</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,952</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,703</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,358</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">726</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,084</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,689</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,137</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:48.35pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,826</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,448</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,215</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">19,663</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(7) Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(7) Earnings Per Share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(7) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2025.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;margin-left:5.4pt"><tr style="height:12.5pt"><td style="width:125.65pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><i>(in thousands)</i></p>
</td><td colspan="3" style="width:131.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:18pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:153pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:131.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:153pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt" valign="top"></td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,048</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,453</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,089</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,409</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,246</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,532</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,278</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,579</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#D3F0FE;width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,246</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,532</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,278</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,579</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:53.45pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.94</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.98</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.86</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.07</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.94</p>
</td><td style="width:15.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.98</p>
</td><td style="width:18pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.86</p>
</td><td style="width:13.5pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.07</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(8) Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">(8) Segment Information</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">8) Segment Information. &#160;The Company operates as one operating segment. &#160;The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its chief executive officer, who reviews financial information presented on a consolidated basis. &#160;The CODM uses consolidated gross profit margin, operating margin, and net income to assess financial performance and allocate resources. &#160;These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table presents selected financial information with respect to the Company&#8217;s single operating segment for the quarters ended June 30, 2025 and June 30, 2024:</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<table style="border-collapse:collapse;width:288.9pt"><tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:129.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Quarter Ended June 30,</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"></td><td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2025</b></p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2024</b></p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Revenues</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">9,953&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">10,400&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Less:</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Standard cost of sales</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">3,763&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">3,307&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other cost of sales</p>
</td><td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">595&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">840&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">5,595&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">6,253&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">56.2%</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">60.1%</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Sales &amp; Marketing</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">525&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">546&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Research &amp; Development</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">135&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">254&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Litigation Fees</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">284&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">637&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">540&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">509&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Other General &amp; Administrative</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">915&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">869&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td style="width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">3,196&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">3,438&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">32.1%</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">33.1%</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other Income</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Interest income</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">679&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">858&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other income (expense)</p>
</td><td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">(40)&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">(85)&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Income before income taxes</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">3,835&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">4,211&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">787&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">758&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Net Income</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">3,048&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">3,453&#160;&#160;</kbd>&#160;</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(9) Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">(9) Subsequent Events</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events. &#160;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements<b>.  </b>After June 30, 2025 through August 11, 2025, the Company made additional repurchases of 10,178 shares of its stock in the open market for $567, at an average price of $55.67 per share.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(3) Inventories: Schedule of Inventory, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;margin-left:9.9pt"><tr style="height:9.45pt"><td style="width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:88.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td style="width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:104.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31,</p>
</td></tr>
<tr style="height:9.45pt"><td style="width:119.75pt" valign="top"></td><td style="width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:88.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:104.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:9.45pt"><td style="background-color:#D3F0FE;width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#D3F0FE;width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:88.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt">971</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:104.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt">1,913</kbd>&#160;</p>
</td></tr>
<tr style="height:9.45pt"><td style="width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:88.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt">1,407</kbd>&#160;</p>
</td><td style="width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:104.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt">1,414</kbd>&#160;</p>
</td></tr>
<tr style="height:9.45pt"><td style="background-color:#D3F0FE;width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#D3F0FE;width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:88.1pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt">5,855</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:104.65pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt">5,485</kbd>&#160;</p>
</td></tr>
<tr style="height:9.45pt"><td style="width:119.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total </p>
</td><td style="width:23.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:88.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt">8,233</kbd>&#160;</p>
</td><td style="width:16.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:104.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt">8,812</kbd>&#160;</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock', window );">Schedule Of Global Revenues By Product Category</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">818</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">207</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,025</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,421</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,386</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,807</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,737</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">365</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,102</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">889</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,130</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:48.35pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,019</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,865</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,088</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,953</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 1H 2025 revenues (USD) by product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr><td style="width:180pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,650</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">400</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,050</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,751</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,952</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,703</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,358</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">726</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:48.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,084</p>
</td></tr>
<tr><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,689</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,137</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:48.35pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,826</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,448</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,215</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">19,663</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Global Revenues by Product Category.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;margin-left:5.4pt"><tr style="height:12.5pt"><td style="width:125.65pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><i>(in thousands)</i></p>
</td><td colspan="3" style="width:131.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:18pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:153pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:131.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:153pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt" valign="top"></td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,048</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,453</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,089</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,409</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,246</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,532</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,278</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,579</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#D3F0FE;width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,246</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,532</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,278</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,579</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:53.45pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:125.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.94</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.98</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.86</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.07</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:125.65pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.94</p>
</td><td style="width:15.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.98</p>
</td><td style="width:18pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.86</p>
</td><td style="width:13.5pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.07</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<table style="border-collapse:collapse;width:288.9pt"><tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:129.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Quarter Ended June 30,</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"></td><td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2025</b></p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2024</b></p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Revenues</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">9,953&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">10,400&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Less:</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Standard cost of sales</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">3,763&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">3,307&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other cost of sales</p>
</td><td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">595&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">840&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">5,595&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">6,253&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">56.2%</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">60.1%</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Sales &amp; Marketing</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">525&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">546&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Research &amp; Development</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">135&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">254&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Litigation Fees</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">284&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">637&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">540&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">509&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Other General &amp; Administrative</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">915&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">869&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td style="width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">3,196&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">3,438&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">32.1%</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">33.1%</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other Income</p>
</td><td style="width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Interest income</p>
</td><td style="background-color:#D3F0FE;width:60.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">679&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">858&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other income (expense)</p>
</td><td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">(40)&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">(85)&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Income before income taxes</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">3,835&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">4,211&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">787&#160;&#160;</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">758&#160;&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Net Income</p>
</td><td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt">3,048&#160;&#160;</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt">3,453&#160;&#160;</kbd>&#160;</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>(3) Inventories: Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory, Finished Goods, Net of Reserves</a></td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 1,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory, Raw Materials, Gross</a></td>
<td class="nump">5,855<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 8,233<span></span>
</td>
<td class="nump">$ 8,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(4) Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">4,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_ObstetricsMember', window );">Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember', window );">Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">4,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_NeonatalMember', window );">Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember', window );">Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 9,953<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="nump">$ 19,663<span></span>
</td>
<td class="nump">$ 21,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_DomesticUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_DomesticUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_ObstetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_ObstetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_NeonatalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_NeonatalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_OutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_OutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,048<span></span>
</td>
<td class="nump">$ 3,041<span></span>
</td>
<td class="nump">$ 3,453<span></span>
</td>
<td class="nump">$ 3,956<span></span>
</td>
<td class="nump">$ 6,089<span></span>
</td>
<td class="nump">$ 7,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,278<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding - diluted</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,278<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 9,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,663<span></span>
</td>
<td class="nump">$ 21,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,133<span></span>
</td>
<td class="nump">13,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">3,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,349<span></span>
</td>
<td class="nump">7,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">3,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,694<span></span>
</td>
<td class="nump">9,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,048<span></span>
</td>
<td class="nump">$ 3,041<span></span>
</td>
<td class="nump">$ 3,453<span></span>
</td>
<td class="nump">$ 3,956<span></span>
</td>
<td class="nump">6,089<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=fil_SingleOperatingSegmentMember', window );">Single Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,953<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_StandardCostOfSales', window );">Standard cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,763<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_OtherCostOfSales', window );">Other cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,595<span></span>
</td>
<td class="nump">$ 6,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_GrossProfitMargin', window );">Gross Profit Margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.20%<span></span>
</td>
<td class="nump">60.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and Marketing Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_LitigationExpense', window );">Litigation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Other Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,196<span></span>
</td>
<td class="nump">$ 3,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_OperatingIncomeMargin', window );">Operating Income Margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.10%<span></span>
</td>
<td class="nump">33.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInterestAndDividendIncome', window );">Other Interest and Dividend Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other Operating Income (Expense), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,048<span></span>
</td>
<td class="nump">$ 3,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrossProfitMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage value of Gross Profit Margin, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_GrossProfitMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LitigationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Litigation Expense, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LitigationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OperatingIncomeMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage value of Operating Income Margin, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OperatingIncomeMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OtherCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Other cost of sales, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OtherCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StandardCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Standard cost of sales, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_StandardCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInterestAndDividendIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInterestAndDividendIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=fil_SingleOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=fil_SingleOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>83</ContextCount>
  <ElementCount>137</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - (1) Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure1BasisOfPresentation</Role>
      <ShortName>(1) Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - (2) Recent Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure2RecentAccountingStandards</Role>
      <ShortName>(2) Recent Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - (3) Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure3Inventories</Role>
      <ShortName>(3) Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - (4) Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensation</Role>
      <ShortName>(4) Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - (5) Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure5WarrantyReserve</Role>
      <ShortName>(5) Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - (6) Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognition</Role>
      <ShortName>(6) Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - (7) Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShare</Role>
      <ShortName>(7) Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - (8) Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformation</Role>
      <ShortName>(8) Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - (9) Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure9SubsequentEvents</Role>
      <ShortName>(9) Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables</Role>
      <ShortName>(3) Inventories: Schedule of Inventory, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables</Role>
      <ShortName>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables</Role>
      <ShortName>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables</Role>
      <ShortName>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails</Role>
      <ShortName>(3) Inventories: Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - (4) Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensationDetails</Role>
      <ShortName>(4) Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails</Role>
      <ShortName>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="utmd-20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails</Role>
      <ShortName>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>utmd-20250630.xsd</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="utmd-20250630_10q.htm">utmd-20250630_10q.htm</File>
    <File>utmd-20250630_cal.xml</File>
    <File>utmd-20250630_def.xml</File>
    <File>utmd-20250630_lab.xml</File>
    <File>utmd-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="448">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>42
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20250630_10q.htm": {
   "nsprefix": "fil",
   "nsuri": "http://www.utahmed.com/20250630",
   "dts": {
    "schema": {
     "local": [
      "utmd-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "inline": {
     "local": [
      "utmd-20250630_10q.htm"
     ]
    },
    "calculationLink": {
     "local": [
      "utmd-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 130,
   "keyCustom": 7,
   "axisStandard": 4,
   "axisCustom": 0,
   "memberStandard": 4,
   "memberCustom": 7,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 83,
   "entityCount": 1,
   "segmentCount": 11,
   "elementCount": 183,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 448,
    "http://xbrl.sec.gov/dei/2025": 29
   },
   "report": {
    "R1": {
     "role": "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets",
     "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "E25Q2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E25Q2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical",
     "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "E25Q2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E25Q2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome",
     "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Y25Q2",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q2",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical",
     "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Y25Q2",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q2",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity",
     "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "E23_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1_StEqComps-CommonStock",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow",
     "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure1BasisOfPresentation",
     "longName": "000080 - Disclosure - (1) Basis of Presentation",
     "shortName": "(1) Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure2RecentAccountingStandards",
     "longName": "000090 - Disclosure - (2) Recent Accounting Standards",
     "shortName": "(2) Recent Accounting Standards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure3Inventories",
     "longName": "000100 - Disclosure - (3) Inventories",
     "shortName": "(3) Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensation",
     "longName": "000110 - Disclosure - (4) Stock-Based Compensation",
     "shortName": "(4) Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure5WarrantyReserve",
     "longName": "000120 - Disclosure - (5) Warranty Reserve",
     "shortName": "(5) Warranty Reserve",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognition",
     "longName": "000130 - Disclosure - (6) Revenue Recognition",
     "shortName": "(6) Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShare",
     "longName": "000140 - Disclosure - (7) Earnings Per Share",
     "shortName": "(7) Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformation",
     "longName": "000150 - Disclosure - (8) Segment Information",
     "shortName": "(8) Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure9SubsequentEvents",
     "longName": "000160 - Disclosure - (9) Subsequent Events",
     "shortName": "(9) Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables",
     "longName": "000170 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Tables)",
     "shortName": "(3) Inventories: Schedule of Inventory, Current (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables",
     "longName": "000180 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)",
     "shortName": "(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables",
     "longName": "000190 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)",
     "shortName": "(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables",
     "longName": "000200 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)",
     "shortName": "(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails",
     "longName": "000210 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Details)",
     "shortName": "(3) Inventories: Schedule of Inventory, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "E25Q2",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E25Q2",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensationDetails",
     "longName": "000220 - Disclosure - (4) Stock-Based Compensation (Details)",
     "shortName": "(4) Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Y25Q2",
      "name": "us-gaap:StockOptionPlanExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
     "longName": "000230 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)",
     "shortName": "(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Y25Q2_ProductOrService-Obstetrics_StGeo-DomesticUs",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q2_ProductOrService-Obstetrics_StGeo-DomesticUs",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
     "longName": "000240 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)",
     "shortName": "(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Y25Q2",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q2",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
     "longName": "000250 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Y25Q2",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250630_StScenario-SingleOperatingSeg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250630_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r472"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts &amp; other receivables, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r562",
      "r563",
      "r564",
      "r565",
      "r587",
      "r623"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total adjustments",
        "totalLabel": "Total adjustments",
        "documentation": "Amount of expense (income); loss (gain); increase (decrease) in liability and (increase) decrease in asset used in operating activity; and cash inflow (outflow) from operating activity, classified as other; in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization {1}",
        "terseLabel": "Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r100",
      "r181",
      "r183",
      "r434",
      "r438",
      "r439",
      "r441",
      "r443"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r63",
      "r84",
      "r107",
      "r108",
      "r109",
      "r143",
      "r150",
      "r158",
      "r161",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r240",
      "r244",
      "r261",
      "r321",
      "r322",
      "r326",
      "r386",
      "r452",
      "r453",
      "r458",
      "r472",
      "r486",
      "r487",
      "r498",
      "r580",
      "r581",
      "r589"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current assets",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r87",
      "r107",
      "r108",
      "r109",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r240",
      "r244",
      "r261",
      "r472",
      "r580",
      "r581",
      "r589"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "fil_BloodPressureMonitoringAndAccessoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "BloodPressureMonitoringAndAccessoriesMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Blood Pressure Monitoring and Accessories",
        "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash &amp; investments",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r81",
      "r435"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash at beginning of period",
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r106"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net increase in cash and cash equivalents",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r48"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r562",
      "r563",
      "r565",
      "r587",
      "r621",
      "r623"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options",
        "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options, shares",
        "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r374"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r29",
      "r374",
      "r392",
      "r623",
      "r624"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2025, 3,216 shares and December 31, 2024, 3,335 shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r205",
      "r208",
      "r328",
      "r472"
     ]
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income",
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total comprehensive income",
        "totalLabel": "Total comprehensive income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r89",
      "r91",
      "r95",
      "r319",
      "r335",
      "r336"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r282",
      "r439",
      "r444",
      "r470",
      "r550"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes {1}",
        "terseLabel": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r65",
      "r558",
      "r561"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r327"
     ]
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit attributable to exercise of stock options",
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability - Femcare IIA",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16",
      "r99",
      "r438",
      "r439",
      "r441",
      "r443"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(4) Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r462"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock dividends",
        "negatedLabel": "Common stock dividends",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "fil_DomesticUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "DomesticUsMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DomesticUsMember",
        "documentation": "Represents the DomesticUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, basic",
        "verboseLabel": "Earnings per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r96",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r203",
      "r220",
      "r235",
      "r238",
      "r259",
      "r260",
      "r320",
      "r337",
      "r445"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per common share (diluted)",
        "verboseLabel": "Earnings per common share (diluted)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r96",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r203",
      "r220",
      "r235",
      "r238",
      "r259",
      "r260",
      "r320",
      "r337",
      "r445"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(7) Earnings Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r139",
      "r140",
      "r141"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r71",
      "r72",
      "r92",
      "r93",
      "r94",
      "r111",
      "r112",
      "r113",
      "r117",
      "r125",
      "r127",
      "r129",
      "r144",
      "r172",
      "r175",
      "r184",
      "r202",
      "r209",
      "r220",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r273",
      "r277",
      "r334",
      "r346",
      "r347",
      "r348",
      "r360",
      "r410"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets - accumulated amortization",
        "negatedLabel": "Other intangible assets - accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r178",
      "r182",
      "r434"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r182",
      "r283",
      "r434"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r179",
      "r318",
      "r453",
      "r457",
      "r464",
      "r465",
      "r466",
      "r467",
      "r471",
      "r472",
      "r574",
      "r575",
      "r586"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r42",
      "r62",
      "r107",
      "r108",
      "r109",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r261",
      "r448",
      "r452",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r580"
     ]
    },
    "fil_GrossProfitMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "GrossProfitMargin",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit Margin",
        "documentation": "Represents the percentage value of Gross Profit Margin, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_GynecologyElectrosurgeryUrologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "GynecologyElectrosurgeryUrologyMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gynecology/Electrosurgery/Urology",
        "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income before provision for income taxes",
        "totalLabel": "Income before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r58",
      "r62",
      "r321",
      "r323",
      "r332",
      "r440",
      "r442",
      "r444",
      "r448",
      "r452",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details {2}",
        "terseLabel": "Details",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r66",
      "r107",
      "r128",
      "r129",
      "r143",
      "r153",
      "r161",
      "r225",
      "r226",
      "r229",
      "r338",
      "r440",
      "r442",
      "r444",
      "r463"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for income taxes",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r50",
      "r557",
      "r583",
      "r584"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable {1}",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable and other receivables",
        "negatedLabel": "Accounts receivable and other receivables",
        "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses {1}",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories {1}",
        "negatedLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets, net",
        "totalLabel": "Other intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r576",
      "r577"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r104",
      "r105"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure3Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(3) Inventories",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r437"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r436",
      "r472"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r107",
      "r108",
      "r109",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r241",
      "r244",
      "r245",
      "r261",
      "r373",
      "r447",
      "r458",
      "r498",
      "r580",
      "r589",
      "r590"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r57",
      "r330",
      "r472",
      "r486",
      "r487",
      "r558",
      "r560",
      "r573",
      "r588"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r80",
      "r107",
      "r108",
      "r109",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r241",
      "r244",
      "r245",
      "r261",
      "r472",
      "r580",
      "r589",
      "r590"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "fil_LitigationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "LitigationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Expense",
        "documentation": "Represents the monetary amount of Litigation Expense, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "fil_NeonatalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "NeonatalMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neonatal",
        "documentation": "Represents the Neonatal, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in financing activities",
        "totalLabel": "Net cash used in financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r51"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure2RecentAccountingStandards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(2) Recent Accounting Standards",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r70",
      "r72",
      "r114",
      "r115",
      "r118",
      "r119",
      "r130",
      "r131",
      "r169",
      "r173",
      "r174",
      "r200",
      "r201",
      "r220",
      "r221",
      "r233",
      "r234",
      "r236",
      "r238",
      "r251",
      "r257",
      "r276",
      "r278",
      "r279",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353"
     ]
    },
    "fil_ObstetricsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "ObstetricsMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obstetrics",
        "documentation": "Represents the Obstetrics, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income",
        "totalLabel": "Operating income",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r440",
      "r444",
      "r448",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ]
    },
    "fil_OperatingIncomeMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "OperatingIncomeMargin",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income Margin",
        "documentation": "Represents the percentage value of Operating Income Margin, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Right-of-Use Assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure1BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(1) Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r73",
      "r74",
      "r76",
      "r354",
      "r355"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r472"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r334"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r262",
      "r269"
     ]
    },
    "fil_OtherCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "OtherCostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other cost of sales",
        "documentation": "Represents the monetary amount of Other cost of sales, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInterestAndDividendIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherInterestAndDividendIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Interest and Dividend Income",
        "documentation": "Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long term liabilities",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r372"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r470"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Selling, General and Administrative Expense",
        "documentation": "Amount of selling, general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "fil_OutsideUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "OutsideUsMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OutsideUsMember",
        "documentation": "Represents the OutsideUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired {1}",
        "negatedLabel": "Common stock purchased and retired",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of dividends",
        "negatedLabel": "Payment of dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "negatedLabel": "Intangible assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "negatedLabel": "Property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock - options",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r282",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r432",
      "r439",
      "r442",
      "r444",
      "r459",
      "r460",
      "r481",
      "r482",
      "r483",
      "r485",
      "r488",
      "r509",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r578",
      "r579",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductWarrantyDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure5WarrantyReserve"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(5) Warranty Reserve",
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r282",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r432",
      "r439",
      "r442",
      "r444",
      "r459",
      "r460",
      "r481",
      "r482",
      "r483",
      "r485",
      "r488",
      "r509",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r578",
      "r579",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income",
        "totalLabel": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r78",
      "r88",
      "r90",
      "r102",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r125",
      "r128",
      "r129",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r203",
      "r220",
      "r235",
      "r238",
      "r239",
      "r242",
      "r243",
      "r260",
      "r261",
      "r321",
      "r323",
      "r333",
      "r359",
      "r393",
      "r408",
      "r409",
      "r468",
      "r469",
      "r497",
      "r512",
      "r580"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r275",
      "r325",
      "r331",
      "r472"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for (recovery of) losses on accounts receivable",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r176"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r431",
      "r440",
      "r441",
      "r452",
      "r591"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r54",
      "r329",
      "r349",
      "r353",
      "r357",
      "r375",
      "r472"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r111",
      "r112",
      "r113",
      "r117",
      "r125",
      "r127",
      "r129",
      "r172",
      "r175",
      "r184",
      "r202",
      "r220",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r238",
      "r246",
      "r248",
      "r249",
      "r252",
      "r258",
      "r271",
      "r273",
      "r346",
      "r348",
      "r360",
      "r623"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r143",
      "r151",
      "r152",
      "r157",
      "r161",
      "r164",
      "r166",
      "r168",
      "r210",
      "r211",
      "r212",
      "r282",
      "r440",
      "r444"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(6) Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r75",
      "r77",
      "r130",
      "r213",
      "r507"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r35",
      "r36",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15"
     ]
    },
    "fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "ScheduleofglobalrevenuesbyproductcategoryTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Global Revenues By Product Category",
        "documentation": "Schedule of Global Revenues by Product Category."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r166",
      "r167",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r321",
      "r322",
      "r323",
      "r324",
      "r363",
      "r364",
      "r365",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r446",
      "r459",
      "r461",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r484",
      "r491",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(8) Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r143",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r439",
      "r440",
      "r441",
      "r444",
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, shares",
        "periodStartLabel": "Equity Balance, shares",
        "periodEndLabel": "Equity Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "fil_SingleOperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "SingleOperatingSegmentMember",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Single Operating Segment",
        "documentation": "Represents the Single Operating Segment, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_StandardCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250630",
     "localname": "StandardCostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standard cost of sales",
        "documentation": "Represents the monetary amount of Standard cost of sales, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r29",
      "r32",
      "r33",
      "r68",
      "r71",
      "r72",
      "r92",
      "r93",
      "r94",
      "r111",
      "r112",
      "r113",
      "r117",
      "r125",
      "r127",
      "r129",
      "r144",
      "r172",
      "r175",
      "r184",
      "r202",
      "r209",
      "r220",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r273",
      "r277",
      "r334",
      "r346",
      "r347",
      "r348",
      "r360",
      "r410"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r166",
      "r167",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r321",
      "r322",
      "r323",
      "r324",
      "r363",
      "r364",
      "r365",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r446",
      "r459",
      "r461",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r484",
      "r491",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r144",
      "r204",
      "r205",
      "r206",
      "r207",
      "r273",
      "r282",
      "r356",
      "r361",
      "r362",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r442",
      "r444",
      "r492",
      "r622"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details {4}",
        "terseLabel": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details {1}",
        "terseLabel": "Details",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details {3}",
        "terseLabel": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r75",
      "r77",
      "r130",
      "r213",
      "r507",
      "r508"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20250630/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r144",
      "r170",
      "r204",
      "r205",
      "r206",
      "r207",
      "r273",
      "r282",
      "r356",
      "r361",
      "r362",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r442",
      "r444",
      "r492",
      "r622"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r29",
      "r54",
      "r216"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r29",
      "r32",
      "r33",
      "r54"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure4StockBasedCompensationDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option compensation expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired, shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r29",
      "r54"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r29",
      "r54"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stockholders' equity",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r32",
      "r33",
      "r52",
      "r376",
      "r392",
      "r411",
      "r412",
      "r472",
      "r498",
      "r558",
      "r559",
      "r560",
      "r573",
      "r588",
      "r623"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, value",
        "periodStartLabel": "Equity Balance, value",
        "periodEndLabel": "Equity Balance, value",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r68",
      "r69",
      "r71",
      "r72",
      "r93",
      "r111",
      "r112",
      "r113",
      "r117",
      "r125",
      "r127",
      "r172",
      "r175",
      "r184",
      "r202",
      "r209",
      "r220",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r258",
      "r264",
      "r265",
      "r270",
      "r272",
      "r277",
      "r347",
      "r348",
      "r358",
      "r376",
      "r392",
      "r411",
      "r412",
      "r417",
      "r486",
      "r487",
      "r497",
      "r558",
      "r559",
      "r560",
      "r573",
      "r588",
      "r623"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure9SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(9) Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TableTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tables/Schedules"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of stock options",
        "verboseLabel": "Dilutive effect of stock options",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r138"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.utahmed.com/20250630/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares outstanding - basic",
        "verboseLabel": "Weighted average shares, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r138"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>43
<FILENAME>0001096906-25-001281-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-25-001281-xbrl.zip
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M,#B^U(X/_^"O[U-OQ-3W3U=JE"]CR_3)".EQOU2"U0\$=7V''$1M$TY&]8-
MNG8QMOP_#AZ60)P8A#,'T-9Z@.HN PIQVG..,2[F5@(]X1!EGS.?<$F)F/G3
M07DGJOB<;*L*H @(9CVT>ZB134;;:@0HU*-[JH^%G6WU 10K<'ZL@12) :B
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M[ P6N]WVD&[/N-9I"E9S,@0-EN&-#5Q^N-9BPE"1JC(JM8B BSY[]OJ(DT\
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M_>V[XZ/UM^_>S?6W[_J=ZV_?35OK;]\-.];?OENXTW=[&T0<F[ZK[^'0K>G
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M=$,UACKSA^$K/-3>AIG&T(+_X^'%X @?OD!R(A 2FJP+T0L'FP?C#YK^ O_
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ML)Q;.1KL7/F3@VD ]R,P3!/U(5I2J=TLU^53.]RO &K@&J800$WPY):6C <
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M&YU8VB>5F_783[3)HPODZPT*7D\XC5&X.X%7L3Q[)9HYQ[Z=B2SB?4]PQ]M
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M&@A&RYQ,X!*_/NE0A$:KO*UA,Z+M%M_'B,T(WA+GX*P%J+I,'IP=3<,X0<\
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MO.>JF5(\1^P=13XOT($PB1F12M%5J8##"AR*GDI\F!^'X"%!1T-12NU&ZS0
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M]J<3^,N',Q!"$,1F_L=9Z,DW!HY+$"3L(318<]E6+;:F%GQC@Q?'X@!LQ T
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MYX4(C]K](6&8)^WG-[$I>*TLRZ=AB1=MQ"/WP$@"Z'&CN85MQ)6=:< # QT
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MTH =!PKW4#<"Q!?P!^C++JQO.OTO_G%4G?XC^Z8BM,H$_$TW=$H&ZBL\\FP
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M _$W)77=C*RN5[4RCZSF)%L8D-FIJ/!64!6>12>N]WO88,>:( ,9+PP/E^G
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MW#(7BR9-R; J-=^1CND-YF-K>]\3W/-11,%U0M1SUQY=?>;J=9+B%5:PJ^Y
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M@TM#N^RU%UEM'.5UN_)7(P+5S^ NWXO]N_41:'?#0<7OKCMW%"O6PJ)"Y1Z
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MK1MTKZ>I[_2/KPGWQEAKKK]9SLD>"+V7CO02 &VOS%U#\R-A[IX^LV-A[E5
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MM,;1-(\'6*XXM804*=#N&\7@@8 9.'U&80Q,/D8Q0D5#*#U&(=;+"&LD&HU
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M$:KZ'O*]JC,K*]GHL/P[RK-#=%A[)Q@(V7.NFR@(4K]O2-*A]CBJ*WBBVS.
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MG86&"\ W$M4<+E+KZEZBB"8AL>!C-'P@VPJ#I:%07V!X1[&("&*"*(4!X)R
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MMK.0MB<;]</:4>^K$8@R03A#T'8&LFS+YN&GVGF8JYD[ -J!=V; *8-Q_>,
M)D!C$&IVC0F/PO%,CV5CG229(TYN$6OYR#?4U@'@(^?N/?5] Q7+KZV%_<$
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M\'0MUG[^ZLG!S SNR3' UJ@0+:*A;3RM='Y8*"CTPN@N0-#6$#// 7-RW(1
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M!\02Y&CY(0>-_E"TAI?AXS3"].W'CGG2A9P4+H*F<+3(]8/ \HAV8E$JUSJ
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M>Q1WE[;)QYO)W>R^W7^MXX0GY)N&MX2-B^<3BIE=!>)I*.(B[#(0J>@W1E6
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M&-"R';S\ ?">76D+:)>>2N?4KZU\-+22OJ[V1&E;KC<L'64>S X&/H;1;Z.
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MC'Z-<6F!Q#*-,/M,3S;+6>@?#&_Y[Q"2BE 3*!5**A"E$BU!@;2G1<J)W*F
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MIBPA><T\77,(CLVB%\\O@L#O&*H1OK6C9N<$T.](J#4T??<=9$+9#2153*1
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M+3(P,C4P-C,P+GAS9%!+ 0(4 Q0    ( '-^#%O\!6XHM+0   88"0 5
M          "  ?4(  !U=&UD+3(P,C4P-C,P7S$P<2YH=&U02P$"% ,4
M" !S?@Q;5F0RX$,)   X=P  %0              @ '<O0  =71M9"TR,#(U
M,#8S,%]C86PN>&UL4$L! A0#%     @ <WX,6]#V6_3O"@  P8@  !4
M         ( !4L<  '5T;60M,C R-3 V,S!?9&5F+GAM;%!+ 0(4 Q0    (
M '-^#%L^P(F572@  $[T 0 5              "  732  !U=&UD+3(P,C4P
M-C,P7VQA8BYX;6Q02P$"% ,4    " !S?@Q;>N/.3&09  "PF $ %0
M        @ $$^P  =71M9"TR,#(U,#8S,%]P<F4N>&UL4$L! A0#%     @
M<WX,6_1GH)+O!@  GQH   \              ( !FQ0! '5T;61?97@S,7HQ
M+FAT;5!+ 0(4 Q0    ( '-^#%M%8VB@: 0  #H,   /              "
M ;<; 0!U=&UD7V5X,S)Z,2YH=&U02P$"% ,4    " !S?@Q;RG9A(UP$  "M
M#   #P              @ %,( $ =71M9%]E>#,R>C(N:'1M4$L%!@     )
-  D 10(  -4D 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>utmd-20250630_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:fil="http://www.utahmed.com/20250630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20250630.xsd" xlink:type="simple"/>
    <context id="D250101_250630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="E25Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="E24Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="I250811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="E24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Y25Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="E23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Y25Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Y25Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="E25Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="E25Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="E25Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="E25Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="E25Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="Y25Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="E25Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="E25Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="E25Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="E25Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="E23_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Y24Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="E24Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Y24Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Y24Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="E24Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="D250101_250630_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Y25Q2_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D250101_250630_StScenario-SingleOperatingSeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D240101_240630_StScenario-SingleOperatingSeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="UsdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="D250101_250630" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="D250101_250630" id="fact2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="D250101_250630" id="fact3">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="D250101_250630" id="fact4">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="D250101_250630" id="fact5">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="D250101_250630" id="ixv-6740">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="D250101_250630" id="ixv-6741">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="D250101_250630" id="ixv-6742">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="D250101_250630" id="ixv-6743">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="D250101_250630" id="ixv-6744">001-12575</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="D250101_250630" id="ixv-6745">UTAH MEDICAL PRODUCTS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D250101_250630" id="ixv-6746">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="D250101_250630" id="ixv-6747">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D250101_250630" id="ixv-6748">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D250101_250630" id="ixv-6749">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D250101_250630" id="ixv-6750">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D250101_250630" id="ixv-6751">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D250101_250630" id="ixv-6752">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D250101_250630" id="ixv-6753">566-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="D250101_250630" id="ixv-6754">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="D250101_250630" id="ixv-6755">UTMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="D250101_250630" id="ixv-6756">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="D250101_250630" id="ixv-6757">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="D250101_250630" id="ixv-6758">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="D250101_250630" id="ixv-6759">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="D250101_250630" id="ixv-6760">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="D250101_250630" id="ixv-6761">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="D250101_250630" id="ixv-6762">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I250811"
      decimals="INF"
      id="ixv-6763"
      unitRef="Shares">3205723</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6764"
      unitRef="USD">82179000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E24" decimals="-3" id="ixv-6765" unitRef="USD">82976000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6766"
      unitRef="USD">3632000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E24" decimals="-3" id="ixv-6767" unitRef="USD">4094000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6768"
      unitRef="USD">8233000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E24" decimals="-3" id="ixv-6769" unitRef="USD">8812000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6770"
      unitRef="USD">331000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="E24" decimals="-3" id="ixv-6771" unitRef="USD">448000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6772"
      unitRef="USD">94375000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E24" decimals="-3" id="ixv-6773" unitRef="USD">96330000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6774"
      unitRef="USD">10257000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E24" decimals="-3" id="ixv-6775" unitRef="USD">9763000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6776"
      unitRef="USD">14193000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="E24" decimals="-3" id="ixv-6777" unitRef="USD">13580000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6778"
      unitRef="USD">56636000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E24" decimals="-3" id="ixv-6779" unitRef="USD">53772000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6780"
      unitRef="USD">54659000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E24" decimals="-3" id="ixv-6781" unitRef="USD">50907000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6782"
      unitRef="USD">1977000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E24" decimals="-3" id="ixv-6783" unitRef="USD">2865000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6784"
      unitRef="USD">120802000</us-gaap:Assets>
    <us-gaap:Assets contextRef="E24" decimals="-3" id="ixv-6785" unitRef="USD">122538000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6786"
      unitRef="USD">737000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="E24" decimals="-3" id="ixv-6787" unitRef="USD">696000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6788"
      unitRef="USD">1517000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E24" decimals="-3" id="ixv-6789" unitRef="USD">3061000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6790"
      unitRef="USD">2254000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E24" decimals="-3" id="ixv-6791" unitRef="USD">3757000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6792"
      unitRef="USD">389000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E24" decimals="-3" id="ixv-6793" unitRef="USD">603000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6794"
      unitRef="USD">0</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent contextRef="E24" decimals="-3" id="ixv-6795" unitRef="USD">0</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6796"
      unitRef="USD">256000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="E24" decimals="-3" id="ixv-6797" unitRef="USD">282000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6798"
      unitRef="USD">370000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E24" decimals="-3" id="ixv-6799" unitRef="USD">469000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6800"
      unitRef="USD">3269000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="E24" decimals="-3" id="ixv-6801" unitRef="USD">5111000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E25Q2"
      decimals="INF"
      id="ixv-6802"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E24"
      decimals="INF"
      id="ixv-6803"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6804"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E24"
      decimals="-3"
      id="ixv-6805"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6806"
      unitRef="Shares">3216000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6807"
      unitRef="Shares">3216000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="E24"
      decimals="-3"
      id="ixv-6808"
      unitRef="Shares">3335000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E24"
      decimals="-3"
      id="ixv-6809"
      unitRef="Shares">3335000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6810"
      unitRef="USD">32000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="E24" decimals="-3" id="ixv-6811" unitRef="USD">33000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6812"
      unitRef="USD">-9362000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E24" decimals="-3" id="ixv-6813" unitRef="USD">-11908000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6814"
      unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E24" decimals="-3" id="ixv-6815" unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6816"
      unitRef="USD">126863000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E24" decimals="-3" id="ixv-6817" unitRef="USD">129302000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6818"
      unitRef="USD">117533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E24" decimals="-3" id="ixv-6819" unitRef="USD">117427000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6820"
      unitRef="USD">120802000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E24" decimals="-3" id="ixv-6821" unitRef="USD">122538000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6822"
      unitRef="USD">9953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6823"
      unitRef="USD">10400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6824"
      unitRef="USD">19663000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6825"
      unitRef="USD">21740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6826"
      unitRef="USD">4358000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6827"
      unitRef="USD">4147000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6828"
      unitRef="USD">8530000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6829"
      unitRef="USD">8722000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6830"
      unitRef="USD">5595000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6831"
      unitRef="USD">6253000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6832"
      unitRef="USD">11133000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6833"
      unitRef="USD">13018000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6834"
      unitRef="USD">2264000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6835"
      unitRef="USD">2560000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6836"
      unitRef="USD">4495000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6837"
      unitRef="USD">5176000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6838"
      unitRef="USD">135000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6839"
      unitRef="USD">255000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6840"
      unitRef="USD">289000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6841"
      unitRef="USD">521000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6842"
      unitRef="USD">2399000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6843"
      unitRef="USD">2815000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6844"
      unitRef="USD">4784000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6845"
      unitRef="USD">5697000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6846"
      unitRef="USD">3196000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6847"
      unitRef="USD">3438000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6848"
      unitRef="USD">6349000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6849"
      unitRef="USD">7321000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6850"
      unitRef="USD">640000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6851"
      unitRef="USD">773000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6852"
      unitRef="USD">1345000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6853"
      unitRef="USD">1689000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6854"
      unitRef="USD">3836000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6855"
      unitRef="USD">4211000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6856"
      unitRef="USD">7694000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6857"
      unitRef="USD">9010000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6858"
      unitRef="USD">788000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6859"
      unitRef="USD">758000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6860"
      unitRef="USD">1605000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6861"
      unitRef="USD">1601000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6862"
      unitRef="USD">3048000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6863"
      unitRef="USD">3453000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6864"
      unitRef="USD">6089000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6865"
      unitRef="USD">7409000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y25Q2"
      decimals="INF"
      id="ixv-6866"
      unitRef="UsdPerShare">0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-6867"
      unitRef="UsdPerShare">0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D250101_250630"
      decimals="INF"
      id="ixv-6868"
      unitRef="UsdPerShare">1.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-6869"
      unitRef="UsdPerShare">2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y25Q2"
      decimals="INF"
      id="ixv-6870"
      unitRef="UsdPerShare">0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-6871"
      unitRef="UsdPerShare">0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D250101_250630"
      decimals="INF"
      id="ixv-6872"
      unitRef="UsdPerShare">1.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-6873"
      unitRef="UsdPerShare">2.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6874"
      unitRef="Shares">3246000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6875"
      unitRef="Shares">3532000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6876"
      unitRef="Shares">3278000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6877"
      unitRef="Shares">3579000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6878"
      unitRef="Shares">3246000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6879"
      unitRef="Shares">3532000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6880"
      unitRef="Shares">3278000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6881"
      unitRef="Shares">3579000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y25Q2"
      decimals="INF"
      id="ixv-6882"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-6883"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="D250101_250630"
      decimals="INF"
      id="ixv-6884"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-6885"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6886"
      unitRef="USD">1828000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6887"
      unitRef="USD">-33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6888"
      unitRef="USD">2546000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6889"
      unitRef="USD">-664000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6890"
      unitRef="USD">4876000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-6891"
      unitRef="USD">3420000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6892"
      unitRef="USD">8635000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6893"
      unitRef="USD">6745000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6894"
      unitRef="USD">6089000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6895"
      unitRef="USD">7409000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6896"
      unitRef="USD">405000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6897"
      unitRef="USD">327000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6898"
      unitRef="USD">1048000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6899"
      unitRef="USD">1023000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6900"
      unitRef="USD">-7000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6901"
      unitRef="USD">-6000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6902"
      unitRef="USD">26000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6903"
      unitRef="USD">26000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6904"
      unitRef="USD">-360000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6905"
      unitRef="USD">-364000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6906"
      unitRef="USD">168000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6907"
      unitRef="USD">131000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6908"
      unitRef="USD">0</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6909"
      unitRef="USD">20000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6910"
      unitRef="USD">-409000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6911"
      unitRef="USD">297000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6912"
      unitRef="USD">-908000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6913"
      unitRef="USD">-441000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6914"
      unitRef="USD">-145000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6915"
      unitRef="USD">-45000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6916"
      unitRef="USD">37000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6917"
      unitRef="USD">66000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6918"
      unitRef="USD">-1531000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6919"
      unitRef="USD">-783000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6920"
      unitRef="USD">1248000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6921"
      unitRef="USD">629000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6922"
      unitRef="USD">7337000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6923"
      unitRef="USD">8038000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6924"
      unitRef="USD">235000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6925"
      unitRef="USD">132000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6926"
      unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6927"
      unitRef="USD">5000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6928"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6929"
      unitRef="USD">27000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6930"
      unitRef="USD">-235000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6931"
      unitRef="USD">-110000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6932"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6933"
      unitRef="USD">390000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6934"
      unitRef="USD">6708000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6935"
      unitRef="USD">9393000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6936"
      unitRef="USD">2018000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6937"
      unitRef="USD">2170000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6938"
      unitRef="USD">-8726000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6939"
      unitRef="USD">-11173000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6940"
      unitRef="USD">827000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6941"
      unitRef="USD">-404000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6942"
      unitRef="USD">-797000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6943"
      unitRef="USD">-3649000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E24" decimals="-3" id="ixv-6944" unitRef="USD">82976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E23" decimals="-3" id="ixv-6945" unitRef="USD">92868000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-6946"
      unitRef="USD">82179000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-6947"
      unitRef="USD">89219000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6948"
      unitRef="USD">2327000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6949"
      unitRef="USD">2791000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-6950"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-6951"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:SharesOutstanding
      contextRef="E24_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6952"
      unitRef="Shares">3335000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6953"
      unitRef="USD">33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6954"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6955"
      unitRef="USD">-11908000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6956"
      unitRef="USD">129302000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E24" decimals="-3" id="ixv-6957" unitRef="USD">117427000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6958"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6959"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6960"
      unitRef="USD">82000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6961"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6962"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-6963"
      unitRef="USD">82000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6964"
      unitRef="Shares">-54000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6965"
      unitRef="USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6966"
      unitRef="USD">-82000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6967"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6968"
      unitRef="USD">-3138000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-6969"
      unitRef="USD">-3221000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6970"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6971"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6972"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6973"
      unitRef="USD">718000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6974"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-6975"
      unitRef="USD">718000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6976"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6977"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6978"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6979"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6980"
      unitRef="USD">1001000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-6981"
      unitRef="USD">1001000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6982"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6983"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6984"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6985"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6986"
      unitRef="USD">3041000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q1"
      decimals="-3"
      id="ixv-6987"
      unitRef="USD">3041000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6988"
      unitRef="Shares">3281000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6989"
      unitRef="USD">33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6990"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6991"
      unitRef="USD">-11190000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6992"
      unitRef="USD">128204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q1"
      decimals="-3"
      id="ixv-6993"
      unitRef="USD">117047000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6994"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-6995"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-6996"
      unitRef="USD">86000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-6997"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-6998"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-6999"
      unitRef="USD">86000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7000"
      unitRef="Shares">-65000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7001"
      unitRef="USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7002"
      unitRef="USD">-86000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7003"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7004"
      unitRef="USD">-3402000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7005"
      unitRef="USD">-3488000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7006"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7007"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7008"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7009"
      unitRef="USD">1828000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7010"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7011"
      unitRef="USD">1828000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7012"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7013"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7014"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7015"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7016"
      unitRef="USD">988000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7017"
      unitRef="USD">988000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7018"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7019"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7020"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7021"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7022"
      unitRef="USD">3048000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7023"
      unitRef="USD">3048000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7024"
      unitRef="Shares">3216000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7025"
      unitRef="USD">32000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7026"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7027"
      unitRef="USD">-9362000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7028"
      unitRef="USD">126862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-7029"
      unitRef="USD">117533000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7030"
      unitRef="Shares">3630000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7031"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7032"
      unitRef="USD">593000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7033"
      unitRef="USD">-10658000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7034"
      unitRef="USD">138341000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E23" decimals="-3" id="ixv-7035" unitRef="USD">128313000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7036"
      unitRef="Shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7037"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7038"
      unitRef="USD">96000</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7039"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7040"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-7041"
      unitRef="USD">96000</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7042"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7043"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7044"
      unitRef="USD">79000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7045"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7046"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-7047"
      unitRef="USD">79000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7048"
      unitRef="Shares">-43000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7049"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7050"
      unitRef="USD">-769000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7051"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7052"
      unitRef="USD">-2221000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-7053"
      unitRef="USD">-2990000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7054"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7055"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7056"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7057"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7058"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-7059"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7060"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7061"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7062"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7063"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7064"
      unitRef="USD">1081000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-7065"
      unitRef="USD">1081000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7066"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7067"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7068"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7069"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7070"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-7071"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7072"
      unitRef="Shares">3588000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7073"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7074"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7075"
      unitRef="USD">-11289000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7076"
      unitRef="USD">138995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-7077"
      unitRef="USD">127742000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7078"
      unitRef="Shares">6000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7079"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7080"
      unitRef="USD">294000</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7081"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7082"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7083"
      unitRef="USD">294000</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7084"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7085"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7086"
      unitRef="USD">52000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7087"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7088"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7089"
      unitRef="USD">52000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7090"
      unitRef="Shares">-95000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7091"
      unitRef="USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7092"
      unitRef="USD">-346000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7093"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7094"
      unitRef="USD">-6056000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7095"
      unitRef="USD">-6403000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7096"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7097"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7098"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7099"
      unitRef="USD">-33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7100"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7101"
      unitRef="USD">-33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7102"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7103"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7104"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7105"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7106"
      unitRef="USD">1052000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7107"
      unitRef="USD">1052000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7108"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7109"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7110"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7111"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7112"
      unitRef="USD">3453000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7113"
      unitRef="USD">3453000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7114"
      unitRef="Shares">3499000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7115"
      unitRef="USD">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7116"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7117"
      unitRef="USD">-11322000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7118"
      unitRef="USD">135339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-7119"
      unitRef="USD">124052000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="D250101_250630" id="ixv-3489">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(1)&lt;/kbd&gt;&lt;kbd style="margin-left:19.8pt"&gt;&lt;/kbd&gt;The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2024. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&#160;&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="D250101_250630" id="ixv-3494">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(2) Recent Accounting Standards. &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. &#160;ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting AUS 2023-09.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. &#160;ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting ASU 2024-03. &lt;/p&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="D250101_250630" id="ixv-3503">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(3)&lt;/kbd&gt;&lt;kbd style="margin-left:19.8pt"&gt;&lt;/kbd&gt;Inventories at June 30, 2025 and December 31, 2024 consisted of the following:&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;margin-left:9.9pt"&gt;&lt;tr style="height:9.45pt"&gt;&lt;td style="width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:88.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:104.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="width:119.75pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:88.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:104.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="background-color:#D3F0FE;width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:88.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"&gt;971&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:104.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"&gt;1,913&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:88.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"&gt;1,407&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:104.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"&gt;1,414&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="background-color:#D3F0FE;width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:88.1pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"&gt;5,855&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:104.65pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"&gt;5,485&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total &lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:88.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"&gt;8,233&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:104.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"&gt;8,812&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D250101_250630" id="ixv-3507">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;margin-left:9.9pt"&gt;&lt;tr style="height:9.45pt"&gt;&lt;td style="width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:88.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:104.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="width:119.75pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:88.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:104.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="background-color:#D3F0FE;width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:88.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"&gt;971&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:104.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"&gt;1,913&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:88.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"&gt;1,407&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:104.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"&gt;1,414&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="background-color:#D3F0FE;width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:88.1pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"&gt;5,855&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:104.65pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"&gt;5,485&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:9.45pt"&gt;&lt;td style="width:119.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total &lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:88.1pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:70pt"&gt;8,233&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:16.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:104.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:87pt"&gt;8,812&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-7120"
      unitRef="USD">971000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E24" decimals="-3" id="ixv-7121" unitRef="USD">1913000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcess
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-7122"
      unitRef="USD">1407000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="E24" decimals="-3" id="ixv-7123" unitRef="USD">1414000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-7124"
      unitRef="USD">5855000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="E24" decimals="-3" id="ixv-7125" unitRef="USD">5485000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-7126"
      unitRef="USD">8233000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E24" decimals="-3" id="ixv-7127" unitRef="USD">8812000</us-gaap:InventoryNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D250101_250630" id="ixv-3594">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(4)&lt;/kbd&gt;&lt;kbd style="margin-left:18pt"&gt;&lt;/kbd&gt;Stock-Based Compensation.  At June 30, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended June 30, 2025 and 2024, the Company recognized $86 and $52, respectively, in stock-based compensation expense. &#160;In the six months ended June 30, 2025 and 2024, the Company recognized $168 and $131, respectively, in stock-based compensation expense.&#160;&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7130"
      unitRef="USD">86000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7131"
      unitRef="USD">52000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-7132"
      unitRef="USD">168000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-7133"
      unitRef="USD">131000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="D250101_250630" id="ixv-3600">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(5) &lt;/kbd&gt;&lt;kbd style="margin-left:18pt"&gt;&lt;/kbd&gt;Warranty Reserve. &#160;The Company&#x2019;s published warranty is: &#x201c;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#x201d; &#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024 or June 30, 2025. &lt;/p&gt;
</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="D250101_250630" id="ixv-3611">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(6) &#160;Global 2Q 2025 revenues (USD) by product category:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Domestic&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Outside US&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;818&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;207&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,025&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,421&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,386&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,807&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,737&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;365&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,102&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;889&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,130&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,019&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,865&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,088&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,953&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 1H 2025 revenues (USD) by product category:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Domestic&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Outside US&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,650&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;400&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,050&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,751&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,952&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,703&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,358&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;726&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,084&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,689&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,137&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,826&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,448&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,215&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;19,663&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock contextRef="D250101_250630" id="ixv-3613">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Domestic&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Outside US&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;818&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;207&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,025&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,421&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,386&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,807&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,737&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;365&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,102&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;889&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,130&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,019&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,865&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,088&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,953&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 1H 2025 revenues (USD) by product category:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Domestic&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Outside US&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,650&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;400&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,050&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,751&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,952&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,703&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,358&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;726&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,084&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,689&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,137&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:48.35pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,826&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,448&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,215&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:48.35pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;19,663&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7134"
      unitRef="USD">818000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7135"
      unitRef="USD">207000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-Obstetrics"
      decimals="-3"
      id="ixv-7136"
      unitRef="USD">1025000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7137"
      unitRef="USD">2421000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7138"
      unitRef="USD">2386000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      id="ixv-7139"
      unitRef="USD">4807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7140"
      unitRef="USD">1737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7141"
      unitRef="USD">365000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-Neonatal"
      decimals="-3"
      id="ixv-7142"
      unitRef="USD">2102000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7143"
      unitRef="USD">889000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7144"
      unitRef="USD">1130000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      id="ixv-7145"
      unitRef="USD">2019000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7146"
      unitRef="USD">5865000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7147"
      unitRef="USD">4088000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7148"
      unitRef="USD">9953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7149"
      unitRef="USD">1650000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7150"
      unitRef="USD">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-Obstetrics"
      decimals="-3"
      id="ixv-7151"
      unitRef="USD">2050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7152"
      unitRef="USD">4751000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7153"
      unitRef="USD">4952000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      id="ixv-7154"
      unitRef="USD">9703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7155"
      unitRef="USD">3358000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7156"
      unitRef="USD">726000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-Neonatal"
      decimals="-3"
      id="ixv-7157"
      unitRef="USD">4084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7158"
      unitRef="USD">1689000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7159"
      unitRef="USD">2137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      id="ixv-7160"
      unitRef="USD">3826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7161"
      unitRef="USD">11448000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7162"
      unitRef="USD">8215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-7163"
      unitRef="USD">19663000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="D250101_250630" id="ixv-3887">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(7) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2025.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;margin-left:5.4pt"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:131.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:153pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Six months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:131.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:153pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,048&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,453&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,089&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,409&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,246&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,532&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,278&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,579&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,246&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,532&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,278&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,579&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.94&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.98&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.86&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.07&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.94&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.98&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.86&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.07&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="D250101_250630" id="ixv-3891">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;margin-left:5.4pt"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:131.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:153pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Six months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:131.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:153pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,048&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,453&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,089&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,409&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,246&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,532&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,278&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,579&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,246&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,532&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,278&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,579&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:125.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.94&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.98&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.86&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.07&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:125.65pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.94&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.98&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.86&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.07&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7166"
      unitRef="USD">3048000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7167"
      unitRef="USD">3453000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-7168"
      unitRef="USD">6089000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-7169"
      unitRef="USD">7409000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7170"
      unitRef="Shares">3246000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7171"
      unitRef="Shares">3532000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-7172"
      unitRef="Shares">3278000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-7173"
      unitRef="Shares">3579000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7174"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7175"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-7176"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-7177"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y25Q2"
      decimals="-3"
      id="ixv-7178"
      unitRef="Shares">3246000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q2"
      decimals="-3"
      id="ixv-7179"
      unitRef="Shares">3532000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D250101_250630"
      decimals="-3"
      id="ixv-7180"
      unitRef="Shares">3278000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D240101_240630"
      decimals="-3"
      id="ixv-7181"
      unitRef="Shares">3579000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y25Q2"
      decimals="INF"
      id="ixv-7182"
      unitRef="UsdPerShare">0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-7183"
      unitRef="UsdPerShare">0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D250101_250630"
      decimals="INF"
      id="ixv-7184"
      unitRef="UsdPerShare">1.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-7185"
      unitRef="UsdPerShare">2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y25Q2"
      decimals="INF"
      id="ixv-7186"
      unitRef="UsdPerShare">0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q2"
      decimals="INF"
      id="ixv-7187"
      unitRef="UsdPerShare">0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D250101_250630"
      decimals="INF"
      id="ixv-7188"
      unitRef="UsdPerShare">1.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D240101_240630"
      decimals="INF"
      id="ixv-7189"
      unitRef="UsdPerShare">2.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="D250101_250630" id="ixv-4115">&lt;p style="font:10pt Times New Roman;margin:0"&gt;8) Segment Information. &#160;The Company operates as one operating segment. &#160;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its chief executive officer, who reviews financial information presented on a consolidated basis. &#160;The CODM uses consolidated gross profit margin, operating margin, and net income to assess financial performance and allocate resources. &#160;These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;The following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the quarters ended June 30, 2025 and June 30, 2024:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:288.9pt"&gt;&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:129.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;Quarter Ended June 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;9,953&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;10,400&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Less:&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Standard cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;3,763&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;3,307&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;595&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;840&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;5,595&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;6,253&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit Margin&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;56.2%&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;60.1%&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Sales &amp;amp; Marketing&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;525&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;546&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Research &amp;amp; Development&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;135&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;254&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Litigation Fees&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;284&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;637&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Amortization&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;540&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;509&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other General &amp;amp; Administrative&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;915&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;869&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;3,196&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;3,438&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income Margin&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;32.1%&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;33.1%&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Interest income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;679&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;858&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other income (expense)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;(40)&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;(85)&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Income before income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;3,835&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;4,211&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Provision for income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;787&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;758&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;3,048&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;3,453&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="D250101_250630" id="ixv-4119">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:288.9pt"&gt;&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:129.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;Quarter Ended June 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;9,953&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;10,400&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Less:&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Standard cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;3,763&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;3,307&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;595&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;840&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;5,595&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;6,253&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit Margin&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;56.2%&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;60.1%&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Sales &amp;amp; Marketing&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;525&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;546&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Research &amp;amp; Development&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;135&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;254&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Litigation Fees&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;284&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;637&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Amortization&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;540&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;509&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other General &amp;amp; Administrative&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;915&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;869&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;3,196&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;3,438&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income Margin&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;32.1%&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;33.1%&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Interest income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;679&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;858&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other income (expense)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;(40)&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;(85)&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Income before income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;3,835&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;4,211&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Provision for income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.3pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;787&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:57.25pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;758&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.3pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"&gt;3,048&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:57.25pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"&gt;3,453&#160;&#160;&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7192"
      unitRef="USD">9953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7193"
      unitRef="USD">10400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fil:StandardCostOfSales
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7194"
      unitRef="USD">3763000</fil:StandardCostOfSales>
    <fil:StandardCostOfSales
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7195"
      unitRef="USD">3307000</fil:StandardCostOfSales>
    <fil:OtherCostOfSales
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7196"
      unitRef="USD">595000</fil:OtherCostOfSales>
    <fil:OtherCostOfSales
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7197"
      unitRef="USD">840000</fil:OtherCostOfSales>
    <us-gaap:GrossProfit
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7198"
      unitRef="USD">5595000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7199"
      unitRef="USD">6253000</us-gaap:GrossProfit>
    <fil:GrossProfitMargin
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-7200"
      unitRef="Pure">0.562</fil:GrossProfitMargin>
    <fil:GrossProfitMargin
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-7201"
      unitRef="Pure">0.601</fil:GrossProfitMargin>
    <us-gaap:SellingAndMarketingExpense
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7202"
      unitRef="USD">525000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7203"
      unitRef="USD">546000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7204"
      unitRef="USD">135000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7205"
      unitRef="USD">254000</us-gaap:ResearchAndDevelopmentExpense>
    <fil:LitigationExpense
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7206"
      unitRef="USD">284000</fil:LitigationExpense>
    <fil:LitigationExpense
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7207"
      unitRef="USD">637000</fil:LitigationExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7208"
      unitRef="USD">540000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7209"
      unitRef="USD">509000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7210"
      unitRef="USD">915000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7211"
      unitRef="USD">869000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7212"
      unitRef="USD">3196000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7213"
      unitRef="USD">3438000</us-gaap:OperatingIncomeLoss>
    <fil:OperatingIncomeMargin
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-7214"
      unitRef="Pure">0.321</fil:OperatingIncomeMargin>
    <fil:OperatingIncomeMargin
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-7215"
      unitRef="Pure">0.331</fil:OperatingIncomeMargin>
    <us-gaap:OtherInterestAndDividendIncome
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7216"
      unitRef="USD">679000</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherInterestAndDividendIncome
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7217"
      unitRef="USD">858000</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7218"
      unitRef="USD">-40000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7219"
      unitRef="USD">-85000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7220"
      unitRef="USD">3835000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7221"
      unitRef="USD">4211000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7222"
      unitRef="USD">787000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7223"
      unitRef="USD">758000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="D250101_250630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7224"
      unitRef="USD">3048000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240630_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7225"
      unitRef="USD">3453000</us-gaap:ProfitLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="D250101_250630" id="ixv-4344">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(9) Subsequent Events. &#160;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements&lt;b&gt;.  &lt;/b&gt;After June 30, 2025 through August 11, 2025, the Company made additional repurchases of 10,178 shares of its stock in the open market for $567, at an average price of $55.67 per share.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
